

Harvard Medical School Curriculum Vitae

Date Prepared: July 9, 2018

Name: Daniel H. Solomon, MD, MPH

Office Address: Brigham and Women's Hospital
Division of Rheumatology, Immunology, and Allergy
75 Francis Street
Boston, MA 02115

Work Phone: 617-732-5356

Work Email: dsolomon@partners.org

Work FAX: 617-732-5505

Place of Birth: Biloxi, MS

Education

1986	B.A.	Psychology	Yale College New Haven, CT
1992	M.D.	Medicine	Yale School of Medicine New Haven, CT
1998	M.P.H.	Clinical Effectiveness	Harvard School of Public Health, Boston, MA

Postdoctoral Training

1992-1993	Intern	Internal Medicine	Boston City Hospital Boston, MA
1993-1995	Resident	Internal Medicine	Brigham and Women's Hospital, Boston, MA
1995-1998	Fellow	Rheumatology	Brigham and Women's Hospital
1995-1998	Fellow	Medicine	Harvard Medical School Boston, MA

Faculty Academic Appointments

1998-2002	Instructor	Medicine	Harvard Medical School
2002-2006	Assistant Professor	Medicine	Harvard Medical School

2006-2012	Associate Professor	Medicine	Harvard Medical School
2012-	Professor	Medicine	Harvard Medical School

Appointments at Hospital/Affiliated Institutions

1993-1995	Resident Physician	Medicine	Brigham and Women's Hospital
1995-1998	Fellow	Clinical Rheumatology	Brigham and Women's Hospital
1998 -	Associate Physician	Medicine	Brigham and Women's Hospital
2014-	Matthew H. Liang Distinguished Chair In Arthritis and Population Health		Brigham and Women's Hospital

Other Professional Positions

2005-2010	Scientific Advisory Board	University of Alabama Center for Education and Research on Therapeutics
2007-	Scientific Advisory Board	Brigham Rheumatoid Arthritis Sequential Study (BRASS)
2016-	Scientific Advisory Board	BWH/NIAMS Joint Biology Consortium

Major Administrative Leadership Positions

2007-	Chief, Section of Clinical Sciences Division of Rheumatology	Brigham and Women's Hospital
2012-2015	Co-Director, Center for Patient-centered Comparative Effectiveness Research	Brigham and Women's Hospital

Committee Service

Local

Brigham and Women's Hospital

1994-2005	Member, Pharmacy and Therapeutics Committee
2000-2002	Member, Human Research Committee (Institutional Review Board),
2003-	Brigham Rheumatoid Arthritis Sequential Study (BRASS), SAB
2005-2008	Member, Physician Council
2005-	Member, Brigham Biomedical Research Institute, Research Oversight Committee
2006-	Member, Brigham Biomedical Research Institute, Bridge Funding Review Committee
2007 -	Member, Division of Rheumatology, Executive Committee
2007-	Member, Division of Rheumatology, Training Committee

Daniel H. Solomon, M.D., M.P.H.

2010-2012 Co-Director, Center for Musculoskeletal Research
 2012- 2016 Co-Director, Center for Patient-centered Comparative Effectiveness Research
 2017- Member, Strategic Planning Committee, Department of Medicine

National

American College of Rheumatology

1998 - 2000 Member, Ad Hoc Committee for Immunologic Testing Guidelines
 2000 - 2005 Member, Abstract Review Committee for Health Services Research
 2001 - 2003 Chair, Abstract Review Committee for Health Services Research
 1999 - 2002 Member, Study Section for Research and Education Foundation
 2004 - 2005 Member, National Committee on Quality Measures for Arthritis Care
 2004 - 2006 Chair, Subcommittee on Classification and Response Criteria
 2004 - 2006 Member, Blue Ribbon Task Force on NSAIDs and Coxibs
 2006 - 2009 Chair, Quality of Care Committee
 2006 - 2009 Member, Quality Leadership Council
 2009- 2013 Member ex-officio, Quality of Care Committee
 2017- Chair, Health Services Abstract Review Committee

Arthritis Foundation

1999 - 2002 Member, Study Section for Clinical Research and Outcomes
 1999 - 2002 Member, Health Promotion Committee
 2000 - 2003 Chairman, Managed Care Sub-Committee
 2017- Member, National Scientific Advisory Board

American Society of Bone and Mineral Research

2008 - 2010 Member, Abstract Review Committee for Osteoporosis Assessment
 2009-2010 Chair, Research Committee of Bone Health National Action Plan
 2012-2016 Member, Task Force to Define Osteoporosis Treatment Outcomes

Other

2003-2005 Member, Expert Panel on Arthritis Quality Indicator Measures, National Committee on Quality Assurance
 2005 - 2008 Member, Scientific Advisory Committee, National Osteoporosis Foundation
 2006- 2017 Member, PRECISION Trial, Executive Committee
 2007- 2012 Member, Veterans Administration RACAT Trial, Data Safety Monitoring Board
 2007-2012 Member, NIH Sjogrens Syndrome Leadership Group
 2008- Consultant for Epidemiology, Consortium of Rheumatic Disease Researchers of North America
 2008-2012 Member, Tanezumab Trial, Data Safety Monitoring Board
 2009-2011 Consultant, Childhood Arthritis and Rheumatology Research Alliance GO Grant
 2010-2011 Member, National Quality Forum Medication Safety Technical Advisory Panel
 2010- Member, AOA Own the Bone Multispecialty Panel
 2011- Member, Governance Committee, National Bone Health Alliance
 2013-2016 Food and Drug Administration, Consultant/Invited Expert:
 Arthritis Advisory Council, Expert Panel on Extended Release Opioids
 2014- Chair, Pharmacoepidemiology Committee, NIA Study of Women's Health Across the Nation (SWAN)
 2016- Chair, Food and Drug Administration Arthritis Advisory Committee

Professional Societies

1993-	Massachusetts Medical Society	Member
1995-	American College of Rheumatology	Member
1995-	Society of General Internal Medicine	Member
1999-	International Society for Pharmacoepidemiology	Member
2000-	Society for Bone Mineral Research	Member

Grant Review Activities

1999-2002	Arthritis Foundation Clinical Therapeutics and Outcomes, Member
2006-2010	Arthritis Foundation Clinical Therapeutics and Outcomes, Member
2006-2010	National Osteoporosis Foundation, Member
2009-	National Institutes of Health, Ad Hoc Reviewer
2010-2011	Chair, Arthritis Foundation Innovative Grant Panel
2010-2011	US Army Medical Research Panel, Reviewer
2012 -2016	Member, CSR/NIH Study Section, Neurological, Aging and Musculoskeletal Epidemiology
2017	Member, Arthritis Research United Kingdom, Site Visit Panel
2018	Ad Hoc Member, CSR/NIH AMSC Panel

Editorial Activities

2004-2008	Editorial Board	Arthritis Foundation Research Communications
2006-2012	Editorial Board	The Rheumatologist (American College of Rheumatology)
2006-2012	Section Editor	Current Opinions in Rheumatology, Epidemiology
2006-2008	Editorial Board	Internal Medicine & Critical Care Pocketbook
2007-2009	Advisory Editor	Arthritis & Rheumatism
2009-2012	Editorial Board	Arthritis Care & Research
2010-2015	Co-Editor	Arthritis & Rheumatism
2015-	Deputy Editor	Arthritis & Rheumatology
2015-	Editorial Board Member	Osteoporosis International

Ad hoc Reviewer: Journal of Rheumatology, JAMA, Rheumatology, Archives of Internal Medicine
Journal of Bone and Mineral Research, American Journal of Medicine, Circulation, Annals of Internal
Medicine, Annals of the Rheumatic Diseases, New England Journal of Medicine

Honors and Prizes

1990	Farr Scholar	Yale School of Medicine
2002	National Service Citation	Arthritis Foundation
2007	Henry Kunkel Young Investigator Award	American College of Rheumatology
2008	Anniversary Honorary Committee Member	Arthritis Foundation

2014	Kenneth L. Baughman Faculty Mentoring Award	Department of Medicine, Brigham and Women's Hospital
2014-	Matthew H. Liang Distinguished Chair in Arthritis and Population Health	

Report of Funded and Unfunded Projects

Funding Information

Past

1998-2001	PI	Partners Community Health Care Inc.	\$50,000
<i>Evaluation of the arthritis self-help program.</i>			
1999-2002	PI	Investigator Award, Arthritis Foundation	\$225,000
<i>Development and validation of a clinical prediction rule for knee MRIs.</i>			
2000-2001	PI	Merck	\$42,500
<i>A randomized trial of intensive education to improve rheumatologist' management practices for glucocorticoid-induced osteoporosis.</i>			
2000-2001	Co-Principal Investigator	Proctor & Gamble	\$7,500
<i>Survey of primary care physicians attitudes toward home densitometry.</i>			
2000-2003	Co-Principal Investigator	Merck	\$250,000
<i>Epidemiologic study of the relationship between rheumatoid arthritis, cardiovascular disease and inflammatory biomarkers in the Nurses Health Study.</i>			
2001-2002	PI	Pfizer	\$150,000
<i>Epidemiologic study of the relationship between selective COX-2 inhibitor use and hypertension.</i>			
2002-2003	PI	Merck	\$795,000
<i>Study of the relationship between selective COX-2 inhibitors and MI.</i>			
2002-2007	PI	NIH – NIAMS K23 AR48616	\$668,600
<i>A Career Development Award to conduct a randomized controlled trial of education to improve the management of osteoporosis.</i>			
2002-2007	PI	Arthritis Foundation, Clinical Grant	\$450,000
<i>A randomized controlled trial to improve the management of osteoporosis in a large state run pharmacy benefits program.</i>			
2002-2004	PI	NIH – NIAMS R55 AR48264	\$100,000
<i>The relationship between rheumatoid arthritis and cardiovascular disease.</i>			

2002-2005	PI	NIH – NIDA RO1 DA 15507	\$646,500
<i>Pain medication use and opioid dependence in patients with arthritis.</i>			
2003-2005	PI	Merck	\$286,875
<i>Randomized controlled trial of patient and physician education for osteoporosis in a large HMO (Horizon Blue Cross Blue Shield of New Jersey)</i>			
2003-2007	PI	Arthritis Foundation, Engalitcheff Award	\$600,000
<i>The quality of and access to disease-modifying anti-rheumatic drugs and biologic therapies in older patients with rheumatoid arthritis.</i>			
2004-2007	PI	Pfizer	\$612,500
<i>Long-term cardiovascular safety of all coxibs and NSAIDs.</i>			
2005-2007	PI	NIH – NIA R21 AG027066	\$337,800
<i>Osteoporosis in postmenopausal women with rheumatoid arthritis.</i>			
2006-2007	PI	Savient Pharmaceuticals	\$175,000
<i>Gout Epidemiology</i>			
2007-2011	Project PI on a program project	NIH – NIAMS P60 AR47782 Katz J. PI	\$4,000,000
<i>Osteoporosis medication adherence: a randomized controlled trial.</i>			
2008-2010	PI	Amgen	\$425,000
<i>Epidemiology of diabetes in psoriasis, psoriatic arthritis, and rheumatoid arthritis.</i>			
2008-2010	PI	AHRQ, DECIDE 290-05-00XX-1 27EHC	\$450,000
<i>Estimating the risk of adverse effects of analgesics in arthritis.</i>			
2008-2010	PI	Arthritis Foundation, Innovation Award	\$200,000
<i>Identifying factors associated with receipt of DMARDs.</i>			
2008-2010	Site PI	AHRQ, CERT U18HS17919	\$2,243,600
<i>Safety Assessment of Anti-TNF Agents in Autoimmune Disease.</i>			
2009-2011	PI	NIH-NIDCR R21 DE018750	\$275,000
<i>Assessing the risk of osteonecrosis of the jaw among persons using bisphosphonates for osteoporosis.</i>			
2010-2012	PI	NIH-NIAMS R21 AR057924	\$275,000
<i>Improving insulin sensitivity with hydroxychloroquine in rheumatoid arthritis.</i>			

2009-2011	Site PI	NIH-NIAMS RC2 AR058989	\$403,461
<i>Comparative effectiveness study of rheumatoid arthritis.</i>			
2009-2014	PI	NIH-NIAMS R01 AR056515-01A1	\$204,496
<i>Defining modifiable disparities in DMARD use among persons with rheumatoid arthritis.</i>			
20013-2015	Co-PI	NIH-NIAMS U34 AR063911	\$446,426
<i>Planning a large scale trial to assess whether treat to target reduces atherosclerosis in RA</i>			
20012-2015	PI	Amgen	\$250,000
<i>Second line osteoporosis treatment patterns</i>			
2013-2016	PI	Pfizer	\$200,000
<i>DMARD Navigator to Improve Adherence</i>			
20013-2015	Co-PI	NIH-NIAMS U34 AR063911	\$446,426
<i>Planning a large scale trial to assess whether treat to target reduces atherosclerosis in RA</i>			

CURRENT

2013-2017	PI	NIH – NIAMS K24 AR055989	\$751,675
<i>Patient centered outcomes research in rheumatic diseases</i>			
20012-2017	Project PI (PI: Katz)	NIH-NIAMS P60 AR47782	\$4,000,000
<i>Improving the Care of RA Through System Re-design</i>			
2011-2017	PI	Lilly	\$840,000
<i>Teriparatide to reduce erosion volume in RA.</i>			
2015-2017	PI	Amgen	\$100,000
<i>Comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis.</i>			
2013-2017	PI	PCORI	\$750,000
<i>Methods to Improve Analysis of Patient Registries</i>			
2014-2019	PI	NIH-NHLBI R01HL119718-01A1	\$1,978,000
<i>Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study</i>			
2016-2020	co-PI	NIH U01 AR068043	\$8,700,000

Treatments Against RA and Effect on FDG PET CT: The TARGET Trial

2017-2020 co-PI Foundation for NIH \$850,000

The TARGET Trial Biomarkers Study

2017-2021 PI NIH \$2,500,000
P30 AR072577

VERITY: Value and Evidence in Rheumatology using bioinformaTics, and advanced analyTics

2018-2019 PI Roche/Genentech \$519,886
Tocilizumab monotherapy: predictors of remission.

Report of Local Teaching and Training:

Teaching of Students in Courses

2007 Chair, American College of Rheumatology Clinical Research Conference.
“Pharmacotherapy in Rheumatic Diseases: Safety, Effectiveness and Value.”

2009 Course Director, Brigham and Women’s Division of Rheumatology
“Short Course on Clinical Research”

2010 Conference Director, Agency for Healthcare Research and Quality. “Systems
Approaches to Improving Osteoporosis Care.”

Harvard Medical School

1999-2002 Orthopedic Surgery Session
1st year medical students Lecturer 2 hr sessions, 1 hr prep

1998-2002 Critical Reading of the Medical Literature
1st year medical students Tutor 2 hrs of discussion, 1 hr prep

2006 Coxibs and Cardiovascular Disease: Continued Controversy
HST Clinical Investigator Training Program
1st year medical students Lecturer 1.5 hrs of lecture, 1 hr prep

2013 The use of different datasets for comparative effectiveness research
Trainees across all Harvard Medical School Departments 1.5 hr session, 4 hrs prep

2017-2018 HST 020 Musculoskeletal Pathophysiology
Course Co-Director 18 hrs, 40 hrs prep

Harvard School of Public Health

2000-present Epidemiology 208
Masters student Preceptor 2 hrs of discussion, 1 hr prep

2005 Clinical Effectiveness

Masters student	Lecture	2 hrs of lectures, 4 hrs of prep
2005	Unanswered questions regarding coxibs, NSAIDs, and cardiovascular disease, Pharmacoevidence	
Masters student	Lecturer	1 hr lecture, 4 hrs prep
2013-2014	Pragmatic Clinical Trials	1 hr leacture, 4 hrs prep
Masters student		

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):

1998-present	Primary Care Elective	
Internal Medicine Residents	Brigham and Women's Hospital	
1998-present	Evidence-Based Journal Club	
Internal Medicine Residents	Brigham and Women's Hospital	
1998-present	Daily clinical Conferences	
Internal Medicine Residents	Brigham and Women's Hospital	
2006	Coxibs and Cardiovascular Disease: Current Controversies Cardiology (Center for Endpoint Confirmation)	
Seminar Presenter	Brigham and Women's Hospital	1 hr of lecture, 1 hr prep
2006	The Safety of Anti-TNF Therapy	
Ground Rounds	Brigham and Women's Hospital	1 hr of lecture, 20 hrs prep
2006	The Safety of Anti-TNF Therapy	
Ground Rounds	Boston University Medical Center- Rheumatology	1 hr of lecture, 2 hrs prep
2007	Pharmacoevidence and Rheumatic Disease Drugs	
Ground Rounds	Brigham and Women's Hospital, Rheumatology Trainees	1 hr of lecture, 2 hrs prep
2008	Quality improvement in Rheumatology	
Grand Rounds	University of Massachusetts Medical Center Rheumatology	1 hr of lecture, 10 hrs prep
2008	Gauging the Quality of Rheumatology Care	
Grand Rounds	Massachusetts General Hospital Rheumatology	1 hr of lecture, 10 hrs prep
2009	Osteoporosis Care	
Residents Teaching Series	Spaulding Rehabilitation Hospital	1 hr of lecture, 3 hrs prep
2013	The Safety of Corticosteroids	
BWH Oral Medicine Grand Rounds		1 hr of lecture, 3 hrs prep

Clinical Supervisory and Training Responsibilities:

1998 - present	Rheumatology Fellows Preceptor	Brigham and Women's Hospital	40 hours per year
1998 – 2007	Internal Medicine Interns, Residents, Medical Students Preceptor; Attending physician	BWH General Medical Service	140 hours per year; 2-4 weeks per year
1999 – present	Medical Students Preceptor	Harvard Medical School, Core 1 Medicine Clerkship	12 hours per year; Several half days
1999 – present	Internal Medicine Residents Preceptor	Brigham and Women's Hospital	12 hours per year; 5 afternoons per year

Formally Supervised Trainees:

2001-2003	Yuka Kiyota MD, MPH Published one manuscript.	Chief Resident (medicine), St. Raphael's Hospital in CT
2002-2004	Charles Morris, MD Published three manuscripts.	Assistant Professor of Medicine, BWH
2002-2003	Jonathan Jacobs, MD Published one manuscript.	Medical Student, HMS
2002-2005	Asra Warsi, BA Published one first author manuscript and two as second author.	Clinical Trial coordinator
2003-2004	Timothy Bhattacharya, MD Published one manuscript.	Assistant Professor (orthopedics), MGH
2004-2005	Danielle Cabral, BA Published one first author manuscript.	Medical Student University of Arizona
2003-2007	Jennifer Polinski, MPH Published two first author manuscripts and three middle author; accepted in doctoral program.	Doctoral student, HSPH
2004-present	Nicola Goodson, MD, PhD Published two first author papers.	Lecturer, University of Liverpool
2004-2005	Michelle Burgener, MPH Published one manuscript; completed Masters in Public Health.	Research coordinator, MGH
2004-present	Mitsu Kinjo, MD, MPH Published three first author papers.	Rheumatologist, Hokkaido Japan
2004-2012	M. Alan Brookhart, PhD Published three first author papers; received an NIH K award.	Assistant Professor of Medicine, BWH

2004-2009	Gladys Ting, MPH	Epidemiologic consultant
Published two first author papers.		
2005-2009	Sonali Desai, MD	Instructor in Medicine, BWH
Published one first author paper; received a grant from the American College of Rheumatology.		
2005-present	Gabriela Schmajuk, MD	Fellow, Rheumatology, Stanford
Published one first author paper; received a grant from the American College of Rheumatology.		
2005-2007	Aimee Shu, MD	Fellow, Endocrinology, Columbia
Published one first author paper.		
2005-2006	Masayo Sato, MPH	Doctoral candidate, University of MD
Published one first author paper.		
2006-2009	Suzanne Cadarette, PhD	Assistant Professor, University Toronto
Published three first author papers; received funding from CIHR.		
2006-2010	Seema Parekh, MD	Fellow, Geriatrics, Harvard
Published two first author papers; received funding on a competitive T32.		
2006-2007	Matthew Stoll, MD, PhD	Assistant Professor of Pediatrics, UT Southwestern
Published one first author paper.		
2006-2008	Mark Lunt, PhD	Senior Lecturer, Manchester UK
Published one first author manuscript and another second author.		
2006-2008	Jessica Agnew-Blais, BA	Masters student, HSPH
Published one first author manuscript; accepted into doctoral program.		
2006-2007	Sindhu Johnson, MD, MPH	Rheumatology fellow, University of Toronto
Published one first author paper.		
2008-2010	Katherine Liao, MD	Assistant Professor Medicine (Rheumatology) BWH
Received T32 and K08. As well, has published several papers.		
2008-2017	Yvonne, Lee, MD, MSc	Associate Professor Medicine (Rheumatology), Northwestern
Received K23, R01 and several other grants. As well, several papers published.		
2009-present	Seoyoung Kim, MD, ScD	Associate Professor (Pharmacoepidemiology), BWH
Many first author papers published; received K23, R01, and several industry grants.		
2010-2012	Femke Prince, MD, PhD	Research Fellow (Rheumatology), BWH
Published one paper and another under review; received travel grant award from Dutch foundation.		
2010-2012	Helena Canhao, MD, PhD	Research Fellow (Rheumatology), BWH
Received HMS-Portugal grant and accepted into the Scholars of Clinical Science Program at HMS. Published one paper.		

2010-2012 Hong Mei, MD Research Fellow (Rheumatology), BWH
Published two papers; received a Masters from HMS.

2011-2016 Lydia Gedmintas, MD Research Fellow (Rheumatology), BWH
Published two papers with two more in progress; enrolled in a Masters program at HSPH.

2011-2017 Siri Lillegraven, MD Research Fellow (Rheumatology), BWH
Published two papers; received a Norwegian grant; received a Masters from HSPH.

2011-2012 Yoon-Kyoon Sung, MD, PhD Research Fellow (Rheumatology), BWH
Two papers under review; received a grant from South Korea.

2012-2013 Maria Mjaavatten, MD, PhD Research Fellow (Rheumatology), BWH
Two papers under review; received a grant from Norway.

2012- Kazuki Yoshida, MD Research Fellow (Rheumatology), BWH
One paper accepted and another under review; received a grant from Japan.

2013-2016 Helga Radner, MD Research Fellow (Rheumatology), BWH
Several papers published on RA and comorbidities; received a grant from Austrian government.

2015-2017 Tzu-Chieh Lin, PhD Research Fellow (Rheumatology), BWH
Several papers on NSAIDs, RA and biologics, Hepatitis B; received a grant from Taiwanese government.

2015- Sara Tedeschi, MD, MPH Instructor in Medicine (Rheumatology), BWH
Several papers on nutritional epidemiology in RA; received a grant from Lupus Foundation.

2015-2016 Mirhelen de Abreu, MD, PhD Professor of Medicine (Rheumatology), Brazil
A grant from ILAR to study dengue and rheumatic disease; one published paper.

2017- Houchen Lyu, MD, PhD Student of Medicine (Orthopaedic Surgery), China
Pursuing a Masters at HMS; studying bone mineral density changes associated with different sequences of osteoporosis medication use.

2018- Julie Lauffenburger, PharmD Research Fellow (Pharmacoepidemiology), BWH
Mentor on her NIH-K award regarding medication adherence among patients with cardiovascular disease.

2018- Riyana Lalani, BA (Medical student candidate) Research Fellow
(Rheumatology), BWH
Mentor on her American College of Rheumatology – Rheumatology Research Foundation Award regarding mucocutaneous toxicities of methotrexate.

Formal teaching of Peers (e.g., CME and other continuing education courses):

2005 “Drug Safety in Rheumatic Disease” Invited Lecturer
Harvard Rheumatology Review Course, Boston MA

2005 Coxibs and Cardiovascular Disease Invited Lecturer
North Shore Medical Center

2006	“Is That Motrin Really Dangerous? Concerns with NSAIDs and Coxibs” Partners Physicians Day, Boston MA	Invited Lecturer
2013	“Drug Safety in Rheumatic Disease” Harvard Rheumatology Review Course, Boston MA	Invited Lecturer
2018	“Drug Safety in Rheumatic Disease” Harvard Rheumatology Review Course, Boston MA	Invited Lecturer
2018	Bench to Bedside: RA and CVD Florida State Rheumatology Society	Invited Lecturer
2018	VERITY/BWH Rheumatology Clinical Research Course NIH-NIAMS Sponsored P30 Enrichment Core Course	Co-Director

Local Invited Presentations:

2000	Rational Use of Nonsteroidal Anti-Inflammatory Drugs Dept. of Rheumatology	Faulkner Hospital	Grand Rounds
2001-present	Cost-Effective Prescribing of NSAIDs (Intensive Review of Internal Medicine) Visiting Physicians	Brigham and Women’s Hospital	Grand Rounds
2003	Medicine	Glucocorticoid Induced Osteoporosis Faulkner Hospital	Grand Rounds
2003	Visiting Physicians	Pharmacoeconomics of Rheumatoid Arthritis Harvard Medical School	Grand Rounds
2004	Rheumatology	Coxibs and Cardiovascular Disease Brigham and Women’s Hospital	Grand Rounds
2004	Medicine	Coxibs and Cardiovascular Disease West Roxbury VA Medical Center	Grand Rounds
2004	Rheumatology	Coxibs and Cardiovascular Disease Beth Israel Deaconess Medical Center	Grand Rounds
2005	Rheumatology	Coxibs and Cardiovascular Disease: Potential Mechanisms for Association Massachusetts General Hospital	Grand Rounds
2005	Cardiology	Coxibs and Cardiovascular Disease: Potential Mechanisms For Association Beth Israel Deaconess Medical Center	Grand Rounds
2005		Coxibs and Cardiovascular Disease	

Medicine	Faulkner Hospital	Grand Rounds
2014 Medicine	Rheumatoid arthritis and cardiovascular disease St. Vincent's Hospital, Worcester	Grand Rounds

Report of Regional, National and International Invited Teaching and Presentations

Regional

2003 Boston University Medical Center	NSAIDs, Coxibs and Cardiovascular Disease	Invited Lecturer
2004 Tufts New England Medical Center	Coxibs and Cardiovascular Disease	
2005 Brigham and Women's Hospital	Coxibs and Cardiovascular Safety" Intensive Review of Internal Medicine, Boston MA,	Invited Lecturer
2014 Beth Israel Deaconess Medical Center	Treat to Target in Rheumatoid Arthritis	Grand Rounds
2018 Massachusetts General Hospital	RA and Cardiovascular Disease	Grand Rounds
2018 Tufts Medical Center	RA and Cardiovascular Disease	Grand Rounds
2018 Brigham and Women's Hospital	NSAID, Coxibs and Safety: An Update	Grand Rounds

National

2003 19 th International Conference on Pharmacoepidemiology, Philadelphia PA	"The accuracy of claims-based diagnosis of acute myocardial infarction in Pharmacoepidemiology research."	Oral Presentation
2003 19 th International Conference on Pharmacoepidemiology, Philadelphia PA	"The diminishing role of patient factors in first COX-2 Inhibitor Prescribing"	Oral Presentation
2003 American College of Rheumatology National Meeting, Orlando FL	"Geriatric pharmacology and rheumatoid arthritis"	Invited Plenary Lecture
2003 American College of Rheumatology National Meeting, Orlando FL	"Rofecoxib and acute myocardial infarction"	Oral Presentation
2003	"Cardiovascular risk factors in rheumatoid arthritis"	Oral Presentation

American College of Rheumatology National Meeting, Orlando FL

2004 "A simple predictive index for total knee replacement outcomes" Oral Presentation

American College of Rheumatology National Meeting, San Antonio TX

2004 "Coxibs and Cardiovascular Disease: Methodologic Challenges" Grand Rounds

Rheumatology, University of Alabama

2004 "Coxibs and Cardiovascular Disease" Grand Rounds
Rheumatology, Hospital for Special Surgery (NY)

2004 "Coxibs and Cardiovascular Disease" Grand Rounds

Rheumatology, Washington University of St. Louis

2004 "Quality Improvement for Osteoporosis Management" Invited Lecture

American College of Rheumatology National Meeting, San Antonio TX

2004 "Coxibs and Cardiovascular Disease: Science and the Public Trust" Grand Rounds Lecturer

Medicine, Stanford Medical Center (Palo Alto CA)

2004 "Coxibs and Cardiovascular Disease: Science and the Public Trust" Grand Rounds Lecturer

Rheumatology, Yale School of Medicine

2004 "Coxibs, NSAIDs, and Cardiovascular Outcomes" Invited Plenary Lecture

Osteoarthritis Research Society International (OARSI), Chicago IL

2005 "Cardiovascular Safety of NSAIDs" Invited Plenary Lecture

American College of Cardiology National Meeting, Orlando FL

2005 "Pharmacoepidemiology of Cardiovascular Risk of COX Inhibition" Invited Plenary Lecture

7th Annual Winter Eicosanoid Conference, Baltimore MD

2005 "Osteoporosis Treatment Compliance" Invited Lecturer

Osteoporosis Briefing on Capital Hill for the Alliance for Aging Research, Washington DC

2005 "Coxibs and Cardiovascular Safety" Invited Plenary Lecture and Moderator

American College of Rheumatology National Meeting, San Diego CA

2005 "Pharmacoepidemiology in Rheumatic Diseases" Invited Moderator and Lecturer

Arthritis Foundation Biennial Research Conference, Atlanta GA

2006	“Pharmacoepidemiology and Coxibs” University of Tennessee – Memphis Medical Center, Clinical Scholars program	Invited Lecturer
2006	“The role of criteria sets in rheumatic disease” American College of Rheumatology Meeting, Washington DC	Moderator
2006	“The Safety of TNF Agents.” University of Pennsylvania, Rheumatology Grand Rounds	Invited Lecturer
2007	“The safety of NSAIDs and coxibs.” American College of Rheumatology Winter Meeting, Aspen CO	Invited Lecturer
2007	“The cost and value of rheumatic therapies.” American College of Rheumatology Winter Meeting, Aspen CO	Invited Lecturer
2007	“The Cardiovascular Safety of NSAIDs and Coxibs: Update 2007” Hospital for Special Surgery, Rheumatology Grand Rounds, New York, New York	Invited Lecturer
2007	“TNF Antagonists and Infection: The Pharmacoepidemiologist’s Perspective.” Hospital for Joint Disease, Rheumatology Grand Rounds, New York, New York	Invited Lecturer
2008	“Academic Progression.” American College of Rheumatology, San Francisco	Invited Lecturer
2008	“Improving Medication Adherence.” Pacific Business Group on Health Quality Connection Lectures	Invited Lecturer
2009	“Patient and Professional Education for Osteoporosis.” National Osteoporosis Foundation	Invited Expert Session
2009	“Safety of Novel Therapies for Rheumatoid Arthritis” National American College of Rheumatology Meeting, Philadelphia PA	Invited Meet the Professor Session
2009	“Quality measures in rheumatology” Cleveland Clinic Quality in Healthcare Forum	Invited Lecturer
2009	“Quality of Care in Rheumatology” University Texas Houston, Rheumatology Rounds	Invited Lecturer
2009	“TNF antagonists and infection” University of Pittsburgh, Rheumatology Rounds	Visiting Professor
2010	“Comparative Effectiveness in Pediatric Rheumatology” Childhood Arthritis and Rheumatology Research Alliance, Chicago IL	Plenary Speaker

2010	“Pharmacoepidemiology and Comparative Effectiveness in Rheumatology” American College of Rheumatology Research Conference for Trainees, Dallas TX	Invited lecturer
2010	“Safety of Novel Therapies for Rheumatoid Arthritis” National American College of Rheumatology Meeting, Atlanta GA	Invited Meet the Professor Session
2010	“Non-Inflammatory Pain in Rheumatoid Arthritis” National Institutes of Health Pain Symposium, Bethesda MD	Invited Speaker
2013	“The role of mid-level practitioners in RA care” American College of Rheumatology	Invited Speaker
2013	Databases for Drug Safety American College of Rheumatology	Invited Speaker
2013	Drug Safety in Rheumatic Diseases Harvard Rheumatology Course	Invited Speaker
2014	Comparative Effectiveness in Rheumatic Diseases American College of rheumatology, Pediatric Conference	Invited Speaker
2014	Inflammatory Basis of CVD: RA as a Case Study Winthrop University Hospital, Medical Grand Rounds	Invited Speaker
2015	Inflammatory Basis of CVD: RA as a Case Study NIH-NIAMS, Intramural Program	Visiting Professor
2017	Bench to Bedside: RA and CVD University of Michigan, Division of Rheumatology	Visiting Professor
2017	Implementation Sciences in Rheumatology American College of rheumatology, National Conference	Invited Speaker
2017	Clinical Year in Review American College of rheumatology, National Conference	Invited Speaker
2017	Sustainability of a Treat to Target Trial American College of rheumatology, National Conference	Abstract Session
2018	Bench to Bedside: RA and CVD University of Texas - Southwestern, Division of Rheumatology	Visiting Professor
2018	Incorporating Fracture Prevention into Healthcare for Patients with Other Common Medical Conditions National Institutes of Health	Invited Speaker

International

2004	“NSAIDs and non-union of humeral shaft fractures: true association or confounding?”	Oral Presentation
20 th International Conference on Pharmacoepidemiology, Bordeaux France		
2006	“Improving Observational Drug Studies: Are Propensity Scores the Answer?”	Invited Lecturer
European League Against Rheumatism, Amsterdam		
2006	“Propensity Score Analyses in Rheumatic Disease.”	Invited Lecturer
ARC Epidemiology Unit, Manchester England		
2008	“Non-selective NSAIDs: Comparative Safety.”	Invited Lecturer
European League Against Rheumatism, Paris		
2008	“Methodologic issues in safety studies for rheumatoid arthritis.”	Invited Visiting Professor
Ogryzlo Day, University of Toronto		
2010	“Osteoporosis medication compliance: .”	Invited Visiting Professor
Graduate Program in Pharmaceutical Sciences, University of Toronto		
2015	“Cardiovascular Disease in Rheumatoid Arthritis”	Invited Plenary Speaker
Korean National Rheumatology Meeting		
2015	“Comparative Effectiveness Research in Rheumatoid Arthritis”	Invited Lecturer
Diakonhjemmet , Oslo Norway		
2018	“Gout Prevention in CANTOS”	Oral Plenary
European League Against Rheumatism, Amsterdam		
2018	“Predicting Disease Activity Using Machine Learning”	Oral Plenary
European League Against Rheumatism, Amsterdam		

Report of Clinical Activities and Innovations

Current Licensure and Certification:

1994	Massachusetts License Registration
1995	Diplomate, American Board of Internal Medicine
1998	Diplomate, American College of Rheumatology

Practice Activities:

Ambulatory Care	Outpatient Clinic	Arthritis Center, BWH	One Session per week
-----------------	-------------------	-----------------------	----------------------

Clinical Innovations:

My clinical practice is located in the Robert B. Brigham Arthritis Center where I see patients one half day each week. The focus of my clinical work is osteoporosis and general rheumatic diseases, with many patients having multi-system rheumatic diseases. I also spend several weeks each year attending on the Rheumatology Consult service.

Report of Education of Patients and Services to the Community

2004 Lupus Conference Speaker
Sponsor: Massachusetts Lupus Foundation
Re: Patients on Managing Bone Disease in Lupus

Report of Scholarship

Peer reviewed publications in print or other media

Research Investigations

1. Ferreri NR, Millet I, Paliwal V, Herzog W, **Solomon D**, Ramaghadran R, Askenase PW. Induction of macrophage TNF alpha, IL-1, IL-6, and PGE2 production by DTH-initiating factors. *Cell Immunol* 1991;137:389-405.
2. **Solomon DH**, Wagner DR, Marenberg ME, Acampora D, Cooney LM, Inouye SK. Predictors of formal home health care use in elderly patients after hospitalization. *J Am Geriatr Soc* 1993;41:961-6.
3. **Solomon DH**, Bates DW, Horsky J, Burdick E, Schaffer JL, Katz JN. Development and validation of a patient satisfaction scale for musculoskeletal care. *Arthrit Care Research* 1999;12:96-100.
4. **Solomon DH**, Katz JN, Bohn R, Mogun H, Avorn J. Non-occupational risk factors for carpal tunnel syndrome. *J Gen Intern Med* 1999;14:310-14. **PMCID: PMC1496575**
5. **Solomon DH**, Shmerling RH, Schur PH, Lew R, Fiskio J, Bates DW. A computer-based intervention to reduce unnecessary serologic testing. *J Rheumatol* 1999;26:2578-84.
6. **Solomon DH**, Levin E, Helfgott SM. Patterns of medication use before and after bone densitometry: factors associated with appropriate osteoporosis treatment. *J Rheumatol* 2000;27:1496-500.
7. **Solomon DH**, Schaffer JL, Katz JN, Horsky J, Burdick E, Nadler E, Bates DW. Can the history and physical examination be used as markers of quality? An analysis of the initial visit note in musculoskeletal care. *Medical Care* 2000;38:383-91.
8. Katz JN, **Solomon DH**, Schaffer JL, Horsky J, Burdick E, Bates DW. Outcomes of care and resource utilization among patients with knee or shoulder disorders treated by general internists, rheumatologists, or orthopedic surgeons. *Am J Med* 2000;108:28-35.
9. Berard A, **Solomon DH**, Avorn J. Patterns of drug use in rheumatoid arthritis. *J Rheumatol* 2000;27:1648-55.

10. **Solomon DH**, Kuntz KM. Should post-menopausal women with rheumatoid arthritis starting corticosteroids be screened for osteoporosis? A cost-effectiveness analysis. *Arthritis Rheum* 2000;43:1967-75.
11. Wang PS, **Solomon DH**, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. *JAMA* 2000;283:3211-6.
12. **Solomon DH**, Bates DW, Schaffer JL, Horsky J, Burdick E, Katz JN. Referrals for musculoskeletal disorders: patterns, predictors, and outcomes. *J Rheumatol* 2001;28:2090-5.
13. **Solomon DH**, Van Houten L, Glynn RJ, Baden L, Curtis K, Schragger H, Avorn J. Academic detailing to improve use of broad spectrum antibiotics at an academic medical center. *Arch Intern Med* 2001;161:1897-902.
14. **Solomon DH**, Stone PH, Glynn RJ, Ganz DA, Gibson CM, Terry R, Avorn J. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. *J Am Coll Cardiol* 2001;38:969-76.
15. **Solomon DH**, Bates DW, Katz JN, Simel DL, Schaffer JL. The rational clinical examination. Does this patient have a torn meniscus or ligament of the knee? Value of the physical examination. *JAMA* 2001;286:1610-20.
16. **Solomon DH**, Ganz DA, Avorn J, Knight EL, Glynn RJ, Gibson CM, Stone PH. Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate catheterization? A clinical decision rule for predicting who will fail medical therapy. *J Clin Epidemiol* 2002;55:121-8.
17. **Solomon DH**, Warsi A, Brown-Stevenson T, Farrell M, Gauthier S, Mikels D, Lee TH. Does self-management education benefit all populations with arthritis? A randomized controlled trial in primary care physician network. *J Rheumatol* 2002;29:362-8.
18. Mandl LA, **Solomon DH**, Smith EL, Lew RA, Katz JN, Shmerling RH. Using antineutrophilic cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? *Arch Intern Med* 2002;162:1509-14.
19. **Solomon DH**, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. *Arch Intern Med* 2002;162:1099-1104.
20. **Solomon DH**, Katz JN, Jacobs JP, La Tourette AM, Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. *Arthritis Rheum* 2002;46:3136-42.
21. **Solomon DH**, Losina E, Baron JA, Fossel AH, Guadagnoli E, Lingard EA, Minder A, Phillips CB, Katz JN. Contribution of hospital characteristics to the volume-outcome relationship: dislocation and infection following total hip replacement. *Arthritis Rheum* 2002;46:2436-44.
22. **Solomon DH**, Glynn RJ, Levin R, Bohn R, Avorn J. The hidden costs of nonselective NSAIDs in older patients. *J Rheumatol* 2003;30:792-8.
23. **Solomon DH**, Connelly MT, Rosen CJ, Dawson-Hughes B, Kiel DP, Greenspan SL, Leib ES, Holick M, Miguel AH, Finkelstein JS. Factors related to the use of bone densitometry: survey responses of 494 physicians in New England. *Osteopor Int* 2003;14:123-9.

24. **Solomon DH**, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation* 2003;107:1303-7.
25. Monach PA, Daily JP, Rodribuez-Herrera G, **Solomon DH**. Tuberculous osteomyelitis presenting as shoulder pain. *J Rheumatol* 2003;30:851-6.
26. Fischer MA, **Solomon DH**, Teich JM, Avorn J. Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. *Arch Intern Med* 2003;163:2585-9.
27. Desai AS, **Solomon DH**, Stone PH, Avorn J. Economic consequences of routine coronary angiography in low and intermediate risk patients with unstable angina. *Am J Cardiol* 2003;92:363-7.
28. Warsi, A, LaValley MP, Wang PS, Avorn J, **Solomon DH**. Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. *Arthritis Rheum* 2003;48:2207-13.
29. **Solomon DH**, Finkelstein JS, Katz JN, Mogun H, Avorn J. Underuse of osteoporosis medications in elderly patients with fractures. *Am J Med* 2003;115:398-400.
30. **Solomon DH**, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Patterns of selective COX-2 inhibitor use: are patient or physician characteristics more important? *Am J Med* 2003;115:715-20.
31. **Solomon DH**, Avorn J, Warsi A, Brown CH, Martin TL, Wright J, Burgener M, Katz JN. Which patients with knee problems are likely to benefit from surgery? Development of a clinical prediction rule. *Arch Intern Med* 2004;164:509-13.
32. **Solomon DH**, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective COX-2 inhibitors and acute myocardial infarction in older adults. *Circulation* 2004;109:2068-73.
33. **Solomon DH**, Karlson EW, Curhan GC. Cardiovascular care and cancer screening in female nurses with and without rheumatoid arthritis. *Arthritis Rheum* 2004;51:429-32.
34. **Solomon DH**, Katz JN, La Tourette AML, Coblyn J. Multifaceted intervention to improve rheumatologists' management of glucocorticoid induced osteoporosis: a randomized controlled trial. *Arthritis Rheum* 2004;51:383-7.
35. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, **Solomon DH**. The accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. *Am Heart J* 2004;148:99-104.
36. Warsi A, Wang PS, LaValley, Avorn J, **Solomon DH**. Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. *Arch Intern Med* 2004;164:1641-49.
37. **Solomon DH**, Brookhart MA, Gandhi TK, Karson A, Gharib S, Orav EJ, Shaykevich S, Licari A, Cabral D, Bates DW. Adherence with osteoporosis practice guidelines: a multi-level analysis of patient, physician, and practice setting characteristics. *Am J Med* 2004;117:919-24.

38. **Solomon DH**, Schneeweiss S, Levin R, Avorn J. The relationship between COX-2 specific inhibitors and hypertension. *Hypertension* 2004;44:140-5.
39. **Solomon DH**, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. *Arthritis Rheum* 2004;50:3444-9.
40. Fischer MA, Schneeweiss S, Avorn J, **Solomon DH**. Medicaid prior authorization programs and the use of cyclooxygenase-2 inhibitors. *N Engl J Med* 2004;351:2187-94.
41. **Solomon DH**, Brookhart MA, Polinski J, Katz JN, Cabral D, Licari A, Avorn J. Osteoporosis Action: design of the Healthy Bones Project trial. *Cont Clin Trials* 2005;26:78-94.
42. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, **Solomon DH**. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: The example of COX-2 inhibitors and myocardial infarction. *Epidemiology* 2005;16:17-24.
43. **Solomon DH**, Finkelstein JS, Wang PS, Avorn J. Statin lipid-lowering drugs and bone mineral density. *Pharmacoepidemiology and Drug Safety* 2005;14:219-26.
44. Schneeweiss S, Glynn RJ, Avorn J, **Solomon DH**. Diminishing influence of patient factors in prescribing of newly marketed COX-2 inhibitors. *J Clin Epidemiol* 2005;58:98-102.
45. Burgener M, Arnold M, Katz JN, Polinski JM, Cabral D, Avorn J, **Solomon DH**. Older adults' knowledge and beliefs about osteoporosis: results of semi-structured interviews used for the development of educational materials. *J Rheumatol* 2005;32:673-7.
46. Bhattacharyya T, Levin R, Vrahas MS, **Solomon DH**. Nonsteroidal anti-inflammatory drugs and non-union of humeral shaft fractures. *Arthritis Rheum* 2005;53:364-7.
47. Ting G, Schneeweiss S, Katz JN, Weinblatt ME, Cabral D, Scranton R, **Solomon DH**. Performance of a rheumatoid arthritis records based index of severity. *J Rheumatol* 2005;32:1679-87.
48. Polinski JM, Brookhart MA, Katz JN, Arnold M, Kristeller J, Trombetta D, Doyle Tadduni ME, Golomb MJ, **Solomon DH**. Educational outreach (academic detailing) regarding osteoporosis in primary care. *Pharmacoepidemiology and Drug Safety* 2005;14:843-850.
49. Winkelmayr W, Schneeweiss S, Avorn J, Patrick A, Levin R, **Solomon DH**. Identification of individuals with chronic kidney disease from Medicare claims data - a validation study. *Am J Kidney Dis* 2005;46:225-32.
50. Cabral D, Katz JN, Weinblatt ME, Ting G, Avorn J, **Solomon DH**. Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. *Arthritis Rheum (Arthritis Care Research)* 2005;53:61-6.
51. Scranton RE, Young M, Lawler L, **Solomon DH**, Gagnon DR, Gaziano JM. Statin use is associated with fewer fractures: Study from a US Veterans population. *Arch Intern Med* 2005;165:2007-12.
52. **Solomon DH**, Avorn J, Katz JN, Finkelstein JS, Polinski J, Arnold M, Brookhart MA. Compliance with osteoporosis medications. *Arch Intern Med* 2005;165:2414-19.

53. **Solomon DH**, Avorn J, Canning C, Wang PS. Lipid levels and bone mineral density. *Am J Med* 2005;118:1414e1-1414e5.
54. Kinjo M, Setoguchi S, Schneeweiss S, **Solomon DH**. Bone mineral density in subjects using central nervous system-active medications. *Am J Med* 2005;118:1414e7-1414e12.
55. Wang PS, Schneeweiss S, Avorn J, Fischer M, Mogun H, **Solomon DH**, Brookhart MA. Risk of death in elderly users of conventional versus atypical antipsychotic medications. *N Engl J Med* 2005;353:2335-41.
56. Fischer MA, Cheng H, Schneeweiss S, Avorn J, **Solomon DH**. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review. *Medical Care* 2006; 44:658-63.
57. **Solomon DH**, Finkelstein JS, Polinski JM, Arnold M, Licari A, Cabral D, Canning C, Avorn J, Katz JN. A randomized controlled trial of mailed osteoporosis education to older adults. *Osteopor Int* 2006;17:760-7.
58. Brookhart MA, Wang PS, **Solomon DH**, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. *Epidemiology* 2006;17:268-75. **PMCID: PMC2715942**
59. **Solomon DH**, Sturmer T, Wang PS, Vaillant G, Cabral D, Mogun H, Avorn J. Prescription opioid use among older adults with arthritis or low back pain. *Arthritis Rheum* 2006;55:35-41.
60. Brookhart MA, **Solomon DH**, Wang P, Glynn RJ, Avorn J, Schneeweiss S. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. *J Clin Epidemiol* 2006;59:18-25.
61. **Solomon DH**, Chibnik LB, Losina E, Huang J, Fossel AH, Husni E, Katz JN. Development of a preliminary index that predicts adverse events after total knee replacement. *Arthritis Rheum* 2006;54:1536-42.
62. Hawker G, Katz JN, **Solomon DH**. The patient's perspective on the Vioxx recall. *J Rheumatol* 2006;33:1082-8.
63. Udell JA, Fischer MA, Brookhart MA, **Solomon DH**, Choudhry NK. Effect of the women's health initiative on osteoporosis therapy and expenditure in Medicaid. *J Bone Min Res* 2006;21:765-71.
64. **Solomon DH**, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and NSAIDs: high risk subgroups and time course of risk. *Arthritis Rheum* 2006;54:1378-89.
65. Sato M, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Avorn J, Ting G, Shadick N, **Solomon DH**. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. *Arthritis Research Therapy* 2006;8:R57. **PMCID: PMC1526615**
66. **Solomon DH**, Katz JN, Cabral D, Patrick AR, Bukowski JF, Coblyn JS. Osteoporosis management among patients with rheumatoid arthritis: evidence for improvement. *Arthritis Rheum (Arthritis Care Research)* 2006;55:873-7.

67. Setoguchi S, **Solomon DH**, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S. TNF alpha antagonist use and cancer in patients with rheumatoid arthritis. *Arthritis Rheumatism* 2006;54:2757-64.
68. Polinski JM, Patrick AR, Truppo C, Breiner L, Egan C, Jan S, Patel M, Chen YT, Weiss TW, **Solomon DH**. Interactive voice response telephone calls to enhance bone mineral density testing. *Am J Managed Care* 2006;12:321-5.
69. Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, **Solomon DH**, Avorn J. Kidney function and use of recommended medications following myocardial infarction in elderly patients. *Clin J Am Soc Nephrol* 2006;1:796-801.
70. Schneeweiss S, **Solomon DH**, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs. An instrumental variable analysis. *Arthritis Rheum* 2006;54:3390-8.
71. **Solomon DH**, Polinski JM, Truppo C, Egan C, Jan S, Patel M, Weiss TW, Chen YT, Brookhart MA. Access to bone mineral density testing in patients at-risk for osteoporosis. *Osteoporos Int* 2006;1:1749-56.
72. **Solomon DH**, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, Canning C, Schneeweiss S. Patterns of cardiovascular risk in rheumatoid arthritis. *Ann Rheum Dis* 2006;65:1608-12.
73. Morris CM, Carrino J, Lang P, **Solomon DH**. Incidental vertebral fractures on chest radiographs: recognition, documentation, and treatment. *J Gen Intern Med* 2006;21:352-356. **PMCID: PMC1484720**
74. **Solomon DH**, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, Schneeweiss S. Immunosuppressive medications and hospitalized cardiovascular events among patients with rheumatoid arthritis. *Arthritis Rheum* 2006;54:3790-8.
75. Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, **Solomon DH**. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. *Am J Med* 2007;120:251-6.
76. **Solomon DH**, Stedman M, Licari A, Weinblatt ME, Maher N, Shadick N. Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries. *Arthritis Rheum (Arthritis Care Research)* 2007;57:234-9.
77. Burge R, Dawson-Hughes B, **Solomon DH**, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *J Bone Mineral Research* 2007;22:465-75.
78. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, **Solomon DH**. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. *J Clin Epidemiol* 2007;60:397-409.
79. van Wijk BLG, Avorn J, **Solomon DH**, Klungel OH, Heerdink ER, de Boer A, Brookhart AM. Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. *J Hypertension* 2007;25:689-97.

80. **Solomon DH**, Polinski JM, Stedman M, Truppo C, Breiner L, Egan C, Jan S, Patel M, Weiss TW, Chen Y-T, Brookhart MA. Improving care of patients at-risk for osteoporosis: a randomized controlled trial. *J Gen Intern Med* 2007;22:362-7. **PMCID: PMC1824772**
81. Charytan DM, Setoguchi S, **Solomon DH**, Avorn J, Winkelmayr WC: Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease. *Kidney Int* 2007;71: 938-45.
82. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME; Setoguchi S; Avorn J; Levin R; **Solomon DH**. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. *Arthritis Rheum (Arthritis Care Research)* 2007;57:928-34.
83. Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth CR, Shrank WS, van Wijk BLG, Cadarette SM, Canning CF, **Solomon DH**. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. *Arch Intern Med* 2007;167:847-52.
84. Schneeweiss S, Setoguchi S, Weinblatt M, Katz JN, Avorn J, Sax PE, Levin R, **Solomon DH**. Anti-TNF α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. *Arthritis Rheum* 2007;56:1754-64.
85. Brookhart MA, Patrick AR, Avorn J, Dormuth C, Shrank WS, Cadarette SM, **Solomon DH**. Adherence to lipid-lowering therapy and the use of preventive health care services: an investigation of the healthy user effect. *Am J Epidemiol* 2007;166:348-54.
86. Setoguchi S, **Solomon DH**, Glynn RJ, Cook EF, Levin R, Schneeweiss S. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between Medicare claims and cancer registry data. *Cancer Causes Control* 2007;18:561-9.
87. Brookhart MA, Avorn J, Polinski JM, Brown TV, Mogun H, **Solomon DH**. The medical license number accurately identifies the prescribing physician in a large pharmacy claims dataset. *Med Care* 2007;45:907-10.
88. Glynn RJ, Brookhart MA, Stedman M, Avorn J, **Solomon DH**. Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers. *Med Care* 2007;45 (Suppl 2):S38-S43.
89. Kulik A, Levin R, Ruel M, Mesana TG, **Solomon DH**, Choudhry NK. Patterns and predictors of statin use after coronary artery bypass graft surgery. *J Thorac Cardiovasc Surg* 2007;134:932-8.
90. Kinjo M, Setoguchi S, **Solomon DH**. Bone mineral density in older patients with rheumatoid arthritis: an analysis of NHANES III. *J Rheumatol* 2007;34:1971-5.
91. **Solomon DH**, Katz JN, Carrino JA, Levin R, Brookhart MA. Percutaneous vertebroplasty among low income medicare beneficiaries. *Spine* 2007;32:2910-14.
92. Kinjo M, Setoguchi S, **Solomon DH**. Bone mineral density in patients with the metabolic syndrome: analysis in a representative population-based sample of adults in the United States. *J Clinical Endocrinol Met* 2007;92:4161-4.

93. **Solomon DH**, Katz JN, Finkelstein JS, Polinski JM, Stedman M, Brookhart MA, Arnold M, Gauthier S, Avorn J. Osteoporosis improvement: a large-scale randomized controlled trial of patient and primary care physician education. *J Bone Mineral Research* 2007;22:1808-15.
94. Shadick, NA, Heller JE, Weinblatt, ME, Maher NE, Cui J, Ginsburg G, Coblyn J, Anderson F, **Solomon DH**, Roubenoff R, Parker A. Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis. *Ann Rheum Dis* 2007;66:1497-1502.
95. **Solomon DH**, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. *Ann Rheum Disease* 2008;67:609-13.
96. Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, **Solomon DH**. Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. *J Rheumatol* 2008;35:319-26.
97. Miller M, Mogun H, Azrael D, Hempstead K, **Solomon DH**. Cancer and the risk of suicide in older Americans. *J Clinical Oncol* 2008;26:4705-7
98. **Solomon DH**, Lunt M, Schneeweiss S. The risk of infection associated with TNF antagonists: making sense of epidemiologic evidence. *Arthritis Rheum* 2008;58:919-28.
99. Setoguchi S, **Solomon DH**, Levin R, Winkelmayr WC: Gender differences in the management and prognosis of myocardial infarction among patients ≥ 65 years of age. *Am J Cardiol* 2008; 101:1531-6.
100. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, **Solomon DH**. Tumor necrosis factor - alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. *Am Heart J* 2008;156:336-41.
101. Cadarette SM, Katz JN, Brookhart MA, Stedman MR, Stürmer T, **Solomon DH**. Relative effectiveness of osteoporosis drugs for nonvertebral fracture prevention: a cohort study. *Ann Intern Med* 2008;148:637-46.
102. **Solomon DH**, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Sturmer T. Subgroup analyses to determine cardiovascular risk associated with NSAIDs and coxibs in specific patient groups. *Arthritis Rheum* 2008;59:1097-1104.
103. Goodson NJ, Brookhart MA, Symmons D, Silman A, **Solomon DH**. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. *Ann Rheum Disease* 2009;68:367-72. **PMCID: PMC2633631**
104. Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, **Solomon DH**. Predictors of discontinuation of TNF inhibitors in patients with rheumatoid arthritis. 2008. *J Rheumatol* 2008;35:1737-44. **PMCID: PMC2756035**
105. Curtis JR, Mudano A, **Solomon DH**, Xi J, Saag KG. Validation of vertebral compression fractures using administrative claims data. *Med Care* 2009;47:69-72. **PMCID: PMC2711626**
106. Agnew-Blais J, Coblyn JS, Katz JN, Anderson RJ, Mehta J, **Solomon DH**. Measuring quality of care for rheumatic diseases using an electronic medical record. *Ann Rheum Dis* 2009;68:680-4. **PMCID: PMC2924631**

107. Parikh S, Mogun H, Avorn J, **Solomon DH**. Osteoporosis medication use in nursing home patients with fractures in one US state. *Arch Intern Med* 2008;168:1111-5.
108. Block EA, **Solomon DH**, Cadarette SM, Mogun H, Choudhry NK. Patient and physician predictors of post-fracture osteoporosis management. *J Gen Intern Med* 2008;23:1447-51. **PMCID: PMC2518009**
109. Winkelmayer W, Setoguchi S, Levin R, **Solomon DH**. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone versus pioglitazone therapy. *Arch Intern Med* 2008;168:2368-75.
110. Winkelmayer WC, Waikar SS, Mogun H, **Solomon DH**. Non-selective and COX-2-selective NSAIDs and acute kidney injury. *Am J Med* 2008;121:1092-8.
111. Kinjo M, Setoguchi S, **Solomon DH**. Anti-histamine therapy and bone mineral density: analysis in a population-based U.S. sample. *Am J Med* 2008;121:1085-91. **NIHMSID: NIHMS224500**
112. Fischer MA, Polinski JM, Servi AD, Agnew-Blais J, Kaci L, **Solomon, DH**. Prior authorization for biologic DMARDs: A description of United States Medicaid programs. *Arthritis Rheum* 2008;59:1611-7. **PMCID: PMC Journal – In Process**
113. Kulik A, Brookhart MA, Levin R, Ruel M, **Solomon DH**, Choudhry NK. Impact of statin use on outcomes after coronary artery bypass graft surgery. *Circulation* 2008;118:1785-92.
114. Stoll ML, **Solomon DH**, Batra KL, Simard JF, Karlson EW, Dellaripa PF, Weinblatt ME, Glass R, Shadick NA. TNF α inhibitors may improve asthma symptoms: A case series of 12 patients with rheumatoid arthritis and asthma. *J Clin Rheumatol* 2009;15:198-200. **PMCID: PMC2954771**
115. Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, Avorn J, **Solomon DH**. Development of a health care utilization data based index for rheumatoid arthritis severity: a preliminary study. *Arthritis Res Ther* 2008;10:R95. **PMCID: PMC2575609**
116. Stedman MR, Gagnon DR, Lew RA, **Solomon DH**, Brookhart MA. An evaluation of statistical approaches for analyzing physician-randomized quality improvement interventions. *Contemp Clin Trials* 2008;29:687-95.
117. King AB, Tosteson AN, Wong JB, **Solomon DH**, Burge RT, Dawson-Hughes B. Inter-state variation in the burden of fragility fractures. *J Bone Miner Res* 2009;24:681-92.
118. Shu A, Stedman M, Polinski J, Jan S, Patel M, Truppo C, Breiner L, Chen Y-T, Weiss TW, **Solomon DH**. Adherence to osteoporosis medications: post-hoc analysis of a randomized controlled trial. *Am J Manag Care* 2009;15:417-424.
119. Shrank WH, Gleason PP, Canning C, Walters C, Heaton AH, Jan S, Patrick A, Brookhart MA, Schneeweiss S, **Solomon DH**, Avorn J, Choudhry NK. Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the target pharmacy label. *J Gen Intern Med* 2009;24:570-8. **PMCID: PMC2669859**
120. **Solomon DH**, Finkelstein JS, Shadick N, LeBoff MS, Winalski C, Stedman M, Glass R, Brookhart MA, Weinblatt ME, Gravallese EM. The relationship between focal erosions and osteoporosis in postmenopausal women with rheumatoid arthritis. *Arthritis Rheum* 2009;60:1624-31. **PMCID: PMC2748798**

121. Stedman MR, Gagnon DG, Lew RA, **Solomon DH**, Losina E, Brookhart MA. A SAS Macro for a clustered permutation Test. *Comput Methods Programs Biomed* 2009;95:89-94.
122. Becker MC, Wang TH, Wisniewski L, Wolsk K, Libby P, Luscher TF, Borer JS, Mascette AM, Husni ME, **Solomon DH**, Graham DY, Yeomans ND, Krum H, Ruschitzka F, Lincoff AM, Nissen SE. Rational, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal anti-inflammatory agents in patients with arthritis. *Am Heart J* 2009;157:606-12.
123. Choudhry NK, Shrank WH, Levin R, Lee LJ, Jan S, Brookhart MA, **Solomon DH**. Measuring concurrent adherence to multiple related medications. *Am J Managed Care* 2009;15:457-64. **PMCID: PMC2873865**
124. Losina E, Walensky RP, Kessler CL, Emrani PS, Reichmann WM, Wright EA, Holt HL, **Solomon DH**, Yelin E, Paltiel AD, Katz JN. Cost-effectiveness of total knee arthroplasty in the US: patient risk and hospital volume. *Arch Intern Med* 2009;169:1113-21. **PMCID: PMC2731300**
125. Shrank WH, Patrick AR, Gleason PP, Canning C, Walters C, Heaton AH, Jan S, Brookhart MA, Schneeweiss S, **Solomon DH**, Wolf MS, Avorn J, Choudhry NK. Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the target pharmacy label. *J Gen Intern Med* 2009;24:570-8.
126. Shrank WH, Choudhry NK, **Solomon DH**, Snedden TM; Lee TH, Glynn R, Brown TV, Jolda C, Spetman M, Brookhart MA, Schneeweiss S, Avorn J. Rationale and design of the SAMPLES trial: a study assessing the effect of cardiovascular medications provided as low-cost, evidence-based generic samples. *Am Heart J* 2009;157:613-9. **PMCID: PMC2683845**
127. Schneeweiss S, Korzenik J, **Solomon DH**, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. *Aliment Pharmacol Ther* 2009;30:253-64.
128. **Solomon DH**, Hochberg MC, Mogun H, Schneeweiss S. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. *Osteoporosis Int* 2009;20:895-901.
129. Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Levin R, **Solomon DH**. Comparative gastrointestinal safety of weekly oral bisphosphonates. *Osteoporos Int* 2009;20:1735-47.
130. **Solomon DH**, Cadarette SM, Choudhry NK, Canning C, Levin R, Sturmer T. A cohort study of thiazolidinediones and fractures in older adults with diabetes. *J Clin Endocrinol Metab* 2009;94:2792-8. **PMCID: PMC2730861**
131. **Solomon DH**, Gleeson T, Iversen M, Avorn J, Brookhart MA, Lii J, Losina E, May F, Patrick A, Shrank WH, Katz JN. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial. *Osteoporosis Int* 2010;21:137-144. **PMCID: PMC2922963**
132. Desai SP, Abramson SB, Buckley L, Crofford LJ, Cush JC, Lovell DJ, Saag KG, **Solomon DH**. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. *Arthritis Rheum* 2008;59(8):1058-73.

133. Lee YC, Chibnik LB, Lu B, Wasan AD, Edwards RR, Fossel AH, Helfgott SM, **Solomon DH**, Clauw DJ, Karlson EW. The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study. *Arthritis Res Ther* 2009;11:R160. **PMCID: PMC2787262**
134. Cisternas MG, Yelin E, Katz JN, **Solomon DH**, Wright EA, Losina E. Ambulatory Visit Utilization in a National, Population-based Sample of Adults with Osteoarthritis. *Arthritis Rheum* 2009;15:1694-703. **PMCID: PMC2836231**
135. Schneeweiss S, Glynn RJ, Avorn J, Mamdani M, Mogun H, **Solomon DH**. NSAID Switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. *Pharmacoepidemiol Drug Safety* 2009;18(12):1134-42.
136. Polinski JM, Cadarette SM, Arnold M, Katz JN, Finkelstein JS, Brookhart MA, Canning CF, Avorn J, **Solomon DH**. High risk patients' readiness to undergo BMD testing for osteoporosis diagnosis in Pennsylvania. *Int Q Community Health Educ* 2008;29(3):223-40. **PMCID:PMC2885851**
137. Cadarette SM, Gagne JJ, **Solomon DH**, Katz JN, Stürmer T. Confounder summary scores when comparing the effects of multiple drug exposures. *Pharmacoepidemiol Drug Safety* 2010;19:2-9. **PMCID: PMC2800174**
138. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, Avorn J, **Solomon DH**, Brookhart MA, Choudhry NK. Patient, physician and payment predictors of statin adherence. *Med Care* 2010;48(3):196-202.
139. Schneeweiss S, Patrick AR, **Solomon DH**, Metha J, Dormuth C, Miller M, Lee J, Wang PS. The comparative safety of antidepressant agents in children regarding suicide attempts and suicides. *Pediatrics* 2010;125(5):876-88. **PMCID:PMC2884182**
140. Schneeweiss S, Patrick AR, **Solomon DH**, Metha J, Dormuth C, Miller M, Lee J, Wang PS. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: A propensity score-adjusted analysis of 9 years of data. *Arch Gen Psychiatry* 2010;67(5):497-506. **PMCID:PMC2884225**
141. Rassen JA, **Solomon DH**, Curtis LH, Herrington L, Schneeweiss S. Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. *Med Care* 2010;48:S83-9. **PMCID: PMC2933455**
142. **Solomon DH**, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Setoguchi Soko, Greenberg JD. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. *Ann Rheum Dis* 2010;69(11):1920-25. **PMCID: PMC2963658**
143. Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H, **Solomon DH**. The Complex Relation Between Bisphosphonate Adherence and Fracture Reduction. *J Clin Endocrinol Metab* 2010;95(7):3251-9. **PMCID:PMC2928897**
144. Demas KL, Keenan BT, **Solomon DH**, Yazdany J, Costenbader KH. Osteoporosis and Cardiovascular Disease Care in Systemic Lupus Erythematosus According to New Quality Indicators. *Semin Arthritis Rheum* 2010;40(3):193-200. **PMCID:PMC2932869**

145. Polinski JM, Cadarette SM, Arnold M, Katz JN, Finkelstein JS, Brookhart MA, Canning C, Avorn J, **Solomon DH**. High-risk patients' readiness to undergo BMD testing for osteoporosis diagnosis in Pennsylvania. *Int Q Community Health Educ*. 2008-2009;29(3):223-40. **PMCID:PMC2885851**
146. Shu AD, Stedman MR, Polinski JM, Jan SA, Patel M, Truppo C, Breiner L, Chen YY, Weiss TW, **Solomon DH**. Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. *Am J Manag Care* 2009;15:417-24. **PMCID: PMC2885859**
147. Lunt M, **Solomon DH**, Rothman K, Glynn RJ, Hyrich K, Symmons DPM, Sturmer T. Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. *Am J Epid* 2009;169:909-17. **PMCID: PMC1656533**
148. **Solomon DH**, Love TJ, Canning C, Schneeweiss S. Risk of Diabetes Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis. *Ann Rheum Disease* 2010;69(12):2114-17 **PMCID: PMCI2991521**
149. Kim SY, Kim MJ, Cadarette SM, **Solomon DH**. Bisphosphonates and risk of atrial fibrillation: a meta-analysis: *Arthritis Res Ther* 2010;12:R30. **PMCID: PMC2875664**
150. Curtis JR, Patkar NM, Jain A, Greenberg J, **Solomon DH**. Validity of physician-reported hospitalized infections in a US arthritis registry. *Rheumatology (Oxford)* 2009;48:1269-72. **PMCID: PMC2744334**
151. Altan E, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, O'Donnell CI, Derber LA, Weinblatt ME, Shadick NA, Bell DA, Cairns E, **Solomon DH**, Holers MV, Rudd PM, Lee DM. Aberrant IgG galactosylation aberrancy precedes disease onset, correlates with disease activity and is prevalent in autoantibodies in rheumatoid arthritis. *Arthritis Rheum* 2010;62(8):2239-48. **PMCID:PMC4118465**
152. Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, **Solomon DH**, Weinblatt ME, Wolfe F, Zink A. A Comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. *Semin Arthritis Rheum* 2010;40(1):2-14.e1. **PMCID:PMC2958101**
153. Nikitovic M, **Solomon DH**, Cadarette SM. Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. *Therap Adv Chronic Dis* 2010;1:149-62. **PMCID:PMC3265538**
154. **Solomon DH**, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. *Ann Rheum dis* 2010;69:2114-7. **PMCID: PMC2991521**
155. **Solomon DH**, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. *Arch Intern Med* 2010;170(22):1968-76.
156. **Solomon DH**, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee, J, Schneeweiss S. The comparative safety of opioids for nonmalignant pain in older adults. *Arch Intern Med* 2010;170(22):1979-86.

157. **Solomon DH.** Strategies for making analgesia safer: the role of comparative effectiveness research. *Arthritis Rheum* 2010;62:1568-70 **PMCID:PMC4083249**
158. Cadarette SM, **Solomon DH,** Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. *Osteoporos Int* 2011; 22(3):943-54 **PMCID:PMC3277855**
159. Desai, SP, Januzzi, JL, Pande, AN, Pomerantsev, EV, Resnic, FS, Fossel, AH, Chibnik, LB, **Solomon, DH.** Comparison of Symptoms, Treatment and Outcomes of Coronary Artery Disease among Rheumatoid Arthritis and Matched Subjects Undergoing Percutaneous Coronary Intervention. *Semin Arthritis Rheum* 2010;40(3):215-21 **PMCID:PMC2982860**
160. Cadarette SM, **Solomon DH,** Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. *Osteoporosis Int* 2010;22(3):943-54 **PMCID:PMC3277855**
161. Rekedal LR, Massarotti E, Garg R, Bhatia R, Gleeson T, Lu B, **Solomon DH.** Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate in diabetic patients with rheumatologic diseases. *Arthritis and Rheumatism* 2010;62(12):3569-73 **PMCID:PMC2992611**
162. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, **Solomon DH,** Weinblatt ME, Shadick NA. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. *Rheumatology* 2010;50(1):40-6
163. Niu NN, Losina E, Martin SD, Wright J, **Solomon DH,** Katz JN. Development and preliminary validation of a meniscal symptom index. *Arthritis Care Research* 2010;63(2):208-15. **PMCID:PMC3025302**
164. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang C-L, Garneau K, **Solomon DH.** Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. *Arthritis Res Ther.* 2010; 12(4): R154 **PMCID: PMC2945054**
165. Husni ME, Losina E, Fossel AH, **Solomon DH,** Mahomed NN, Katz JN. Decreasing medical complications for total knee arthroplasty: effect of critical pathways on outcomes. *BMC Musculoskelet Disord.* 2010; 11: 160 **PMCID: PMC2918540**
166. Hiraki LT, Lu B, Alexander SR, Shaykevich T, Alarcón GS, **Solomon DH,** Winkelmayr W, Costenbader KH, End-Stage Renal Disease due to Lupus Nephritis among Children in the U.S., 1995-2006. *Arthritis Rheum* 2011;63(7):1688-97 **PMCID:PMC3128195**
167. Kim SY, Schneeweiss S, Katz JN, Levin R, **Solomon DH.** Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. *J Bone Miner Res* 2010;26(5):993-1001 **PMCID:PMC3179299**
168. Kim S, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, **Solomon DH,** Validation of rheumatoid arthritis diagnoses in health care utilization data. *Arthritis Res & Ther* 2011;13(1):R32 **PMCID:PMC3241376**
169. Parikh S, Brookhart MA, Stedman M, Avorn J, Mogun H, **Solomon DH,** Correlations of nursing home characteristics with prescription of osteoporosis medications, *Bone* 2011;48(5):1164-8 **PMCID:PMC3096758**

170. Liao KP, Weinblatt ME, Cui J, Iannaccone C, Chibnik, L, Lu B, Coblyn JS, Shadick NA, **Solomon DH**, Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study. *Rheumatology (Oxford)* 2011;50(8):1473-9 **PMCID:PMC3133482**
171. Kim SY, **Solomon DH**, Pharmacotherapy: Comparative safety of nonsteroidal anti-inflammatory drugs. *Nat Rev Cardiol.* 2011;8(4):193-5 **PMCID:PMC3725754**
172. Gagne JJ, Patrick AR, Mogun H, **Solomon DH**. Antidepressants and fracture risk in older adults: a comparative safety analysis. *Clin Pharmacol Ther* 2011;89(6):880-887. **PMCID:PMC4836179**
173. Desai SP, Turchin A, Szent-Gyorgyi LE, Weinblatt M, Coblyn J, **Solomon DH**, Kachalia A. Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality. *Rheumatology (Oxford)* 2011;50(2):366-72 **PMCID:PMC3021950**
174. **Solomon DH**, Brookhart MA, Tsao P, Sundaresan D, Andrade SE, Mazor K, Yood R. Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. *Osteoporos Int.* 2011;22(6):1737-43 **PMCID:PMC4843120**
175. Garneau K, Iversen M, Jan S, Parmar K, Tsao P, **Solomon DH**. Rheumatoid arthritis decision making: many information sources but not all rated as useful. *J Clin Rheumatol.* 2011;17(5):231-5
176. **Solomon DH**, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. *JAMA.* 2011;305(24):2525-31.
177. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed GW, Tsao P, Farkouh ME, Nasir A, Setoguchi S, **Solomon DH**. TNF antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. *Ann Rheum Dis* 2011;70(4):576-82.
178. Chang TI, Desai M, **Solomon DH**, Winkelmayr WC. Association of kidney function with long-term medication adherence after myocardial infarction in the elderly. *Clin J Am Soc Nephrol* 2011;6(4):864-9 **PMCID:PMC3069380**
179. Curtis JR, Larson J, Delzell ED, Brookhart MA, Cadarette S, Chewblowski R, Judd S, Safford M, **Solomon DH**, LaCroix A. Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. *Med Care* 2010;49(5):427-35
180. Kuriya B, Hernández-Díaz S, Liu J, Bermas BL, Daniel G, **Solomon DH**. Patterns of drug use during pregnancy in rheumatoid arthritis. *Arthritis Care Res* 2011;63(5):721-8
181. Iversen MD, Vora R, Servi A, **Solomon DH**. Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. *J Geriatric Phys Ther* 2011;34(2):72-81 **PMCID:PMC3181084**
182. **Solomon DH**, Mogun H, Garneau K, Fischer M. The risk of fractures in older adults using anti-hypertensive medications. *J Bone Miner Res.* 2011;26(7):1561-7

183. Rassen JA, **Solomon DH**, Glynn RJ, Schneeweiss S. Simultaneously assessing intended and unintended treatment effects of multiple treatment options: Practical considerations of a matrix study design. *Pharmacoepidemiol Drug Saf.* 2011;20(7):675-83
184. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME, **Solomon DH**. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. *Arthritis Res Ther.* 2011;13(3):R83 **PMCID:PMC3218896**
185. Kim SY, **Solomon DH**, Liu J, Chang CL, Daniel GW, Schneeweiss S. Accuracy of identifying neutropenia diagnoses in outpatient claims data. *Pharmacoepidemiol Drug Saf.* 2011;20(7):709-13 **PMCID:PMC3142869**
186. Patrick AR, Schousboe JT, Losina E, **Solomon DH**. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. *J Clin Endocrinol Metab.* 2011;96(9):2762-70 **PMCID:PMC3167669**
187. Berry SD, Zhang Y, Lipsitz LA, Mittleman MA, **Solomon DH**, Kiel DP. Antidepressant Prescriptions: an acute window for falls in the nursing home. *J Gerontol A Biol Sci Med Sci.* 2011;66(10):1124-30 **PMCID:PMC3202899**
188. Burden AM, Paterson JM, **Solomon DH**, Mamdani M, Juurlink DN, Cadarette SM. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. *Osteoporos Int* 2012;23(3):1075-1082 **PMCID:PMC3277689**
189. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, Avorn J, **Solomon DH**, Brookhart MA, Choudhry NK. Patient, physician, and payment determinants of statin adherence. *Med Care.* 2010;48(3):196-202
190. Miller M, Sturmer T, Azreal D, Levin R, **Solomon DH**. Opioid analgesics and the risk of fractures among older adults with arthritis. *J Am Geriatr Soc.* 2011;59(3):430-8
191. **Solomon DH**, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with TNF-Inhibitors in RA: A review of their methodologies and results. *Arthritis Rheum.* 2011;64(1):21-32 **PMCID:PMC3241884 NIHMSID: NIHMS320565**
192. Lillegraven S, Prince FHM, Bykerk VP, Shadick NA, Lu B, Frits M, Iannaccone CK, Kvien TK, Haavardsholm EA, Weinblatt ME, **Solomon DH**. Remission and radiographic outcome in rheumatoid arthritis: Application of the 2011 ACR/EULAR criteria in an observational cohort. *Ann Rheum Dis.* 2012; 71(5):681-6
193. Kesselheim AS, Myers JA, **Solomon DH**, Winkelmayer WC, Levin R, Avorn J. The prevalence and cost of unapproved uses of top selling orphan drugs. *PLoS ONE* 2012. 2012;7(2):e81894 **PMCID:PMC3283698**
194. **Solomon DH**, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN. Use of Disease-Modifying Medications for Rheumatoid Arthritis by Race and Ethnicity in the National Ambulatory Medical Care Survey. *Arthritis Care Res.* 2012;64(2):184-9 **PMCID:PMC3266957**
195. Schmajuk G, Trivedi AN, **Solomon DH**, Yelin E, Trupin L, Chakravarty EF, Yazdany J. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. *JAMA* 2011;305(5):480-6 **PMCID:PMC3172813**

196. Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, **Solomon DH**, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. *Arthritis Rheum.* 2012;64(4):1263-71 **PMCID:PMC3315602**
197. Garneau KL, Iversen MD, Tsao H, **Solomon DH**. Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement. *Arthritis Research Therapy.* 2011;13(6):R189 **PMCID:PMC3334638**
198. SY Kim, S Schneeweiss, J Liu, **DH Solomon**. Effects of Disease-Modifying Antirheumatic Drugs on Fracture Risk in Rheumatoid Arthritis; a Population-based Cohort Study. *J Bone Miner Res.* 2012;27(4):789-96. **PMCID:PMC3725780**
199. **Solomon DH**, Iversen MD, Avorn J, Gleeson T, Brookhart MA, Patrick AR, Rekedal L, Shrank WH, Lii J, Losina E, Katz JN. Osteoporosis telephonic intervention to improve medication adherence (OPTIMA): a large pragmatic randomized controlled trial. *Arch Intern Med.* 2012;172(6):477-83. **PMCID:PMC3905804**
200. Villeneuve E, Nam JL, Bell M, Deighton C, Felson DT, Hazes JM, McInnes I, Silman AJ, **Solomon DH**, Thompson A, White PH, Bykerk V, Emery P. A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. *Ann Rheum Dis.* 2013: 72(1):12-22.
201. **Solomon DH**, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. *Osteoporosis Int.* 2013: 24(1):237-44.
202. Lee YC, Lu B, Boire G, Haraoui B, Hitchon CA, Pope JE, Thorne JC, Keystone EC, **Solomon DH**, Bykerk VP. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. *Ann Rheum Dis.* 2012;72(6):949-54. **PMCID:PMC3488361**
203. Winthrop KL, Chen L, Fraunfelder FW, Ku JH, Varley CD, Suhler E, Hills WL, Gattley D, Baddley KW, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Herrinton LJ, Fraunfelder FT, Saag KG, Lewis JD, **Solomon DH**, Curtis JR. Initiation of anti-TNF therapy and the risk of optic neuritis; from the Safety Assessment of Biologic Therapy (SABER) Study. *Am J Ophthalmol.* 2013: 155(1):183-9. **PMCID:PMC4142597**
204. Choudhry NK, Fischer MA, Avorn J, Lee JL, Schneeweiss S, **Solomon DH**, Berman B, Jan S, Lii J, Mahoney JJ, Shrank WH. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. *Journal of the American College of Cardiology.* 2012: 60(18):1817-24.
205. Gelber AC, **Solomon DH**. If life serves up a bowl of cherries, and gout attacks are "the pits"... implications for therapy. *Arthritis Rheum.* 2012: 64(12): 3827-30.
206. Kim SY, Schneeweiss S, Myers J, Liu J, **Solomon DH**. No difference in cancer screening rates in patients with rheumatoid arthritis compared to the general population. *Arthritis Rheum.* 2012: 64(10):3076-82. **PMCID:PMC3462284**
207. **Solomon DH**, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. *Osteoporosis Int.* 2013: 24(1):237-44.

208. Fisher M.C., Furer V., Hochberg M.C., Greenberg J.D., Kremer J., Curtis J.R., Reed G., Harrold L.R., **Solomon D.H.** Malignancy Validation in a United States Registry of Rheumatoid Arthritis Patients. *BMC Musculoskeletal Disorders* 2012;13:85 **PMCID:PMC3403943**
209. Lee YC, Lu B, Boire G, Haraoui B, Hitchon CA, Pope JE, Thorne JC, Keystone EC, **Solomon DH**, Bykerk VP. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. *Ann Rheum Dis.* 2013; 72(6):949-54 **PMCID:PMC3488361**
210. Palmsten K, Hernández-Díaz S, Kuriya B, **Solomon DH**, Setoguchi S. Use of Disease-Modifying Antirheumatic Drugs During Pregnancy and Risk of Preeclampsia. *Arthritis Care Res (Hoboken)*. 2012;64(11):1730-1738 **PMCID:PMC3514881**
211. Canhao H; Rodrigues A; Filipa Mourao A; Martins F; Jose Santos M; Canas-Silva J; Polido-Pereira J; Pereira Silva JA; Costa JA; Araujo D; Silva C; Santos J; Duarte C; Pereira da Silva JA; Pimentel-Santos FM; Branco JC; Karlson E; Fonseca JE; **Solomon DH.** Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. *Rheumatology* 2012; 51(11):2020-6. doi: 10.1093/rheumatology/kes184. Epub 2012 Jul 28. **PMCID: PMC3475979.**
212. Desai SP, Lu B., Szent-Gyorgyi L, Bogdanova A, Turchin A, Weinblatt ME, Coblyn J, Greenberg JO, Kachalia A, **Solomon DH.** Increasing Pneumococcal Vaccination for Immunosuppressed Patients: A Cluster Quality Improvement Trial. *Arthritis & Rheumatism.* 2012;65(1): 39-47.
213. Liao, KP, **Solomon, DH.** Traditional cardiovascular risk factors, inflammation, and cardiovascular risk in rheumatoid arthritis. *Rheumatology.* 2013;52(1): 45-52. **PMCID:PMC3521444**
214. Massengale M, Bing L, Pan JJ, Katz JN, **Solomon DH.** Adipokine hormones and hand osteoarthritis: Radiographic severity and pain. *PLOS ONE.* 2012;7(10):e47860. **PMCID:PMC3482224**
215. Lee YC, Lu B, Edwards RR, Wasan AD, Nassikas NJ, Clauw DJ, **Solomon DH**, Karlson EW. The role of sleep problems in central pain processing in rheumatoid arthritis. *Arthritis Rheum.* 2013;65(1):59-68. **PMCID:PMC3535519**
216. Lillegraven S, Paynter N, Prince FHM, Shadick NA, Haavardsholm EA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, **Solomon DH.** Performance of matrix-based risk models for rapid radiographic progression in a cohort with established rheumatoid arthritis. *Arthritis Care Res* 2013; 65(4):526-33. doi: 10. 1002/acr.21870. **PMCID: PMC3594116**
217. Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, **Solomon DH**, Kim SJ, Rothman KJ, Liu J, Avorn J. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. *BMC Med Res Methodol*, 2012;12(1):180. **PMCID:PMC3533513**
218. Herrington LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, Griffin MR, **Solomon DH**, Saag KG, Lewis JD. Association between anti-TNF- α Therapy and all-cause mortality. *Pharmacoepidemiol Drug Saf.* 2012;21(12); 1311-20. **PMCID:PMC3565563**
219. **Solomon DH**, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. *Ann Rheum Dis* 2013;72(11):1813-8.

220. Rassen JA, Shelat AA, Myers JA, Glynn RJ, **Solomon DH**, Schneeweiss S. Matching by propensity score in cohort studies with three treatment groups. *Epidemiology*. 2013;24(3):401-9.
221. **Solomon DH**, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya, B, Liu L, Griffin MR, Lewis JD, Rassen JA. The Relationship of Cardiovascular Risk in Rheumatoid Arthritis Comparing TNF α Blockade with Non-Biologic DMARDs. *Am J Med*. 2013;126(8):730.e9-730.e17
222. Gedmintas L, **DH Solomon**, SC Kim. Bisphosphonates and Risk of Subtrochanteric, Femoral Shaft, and Atypical Femur Fracture: A Systematic Review and Meta-analysis. *J Bone Miner Res*. 2013;28(8):1729-1737. **PMCID:PMC3713078**
223. Najm M, **Solomon DH**, Woo SB, Treister, N. Resource Utilization in Cancer Patients with Bisphosphonate-Associated Osteonecrosis of the Jaw. *Oral Dis* 2014;20(1);94-9. **PMCID:PMC3661763**
224. Kim SC, Yelin E, Tonner C, **Solomon DH**. Changes in Use of Disease Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis in the U.S. for the period 1983-2009. *Arthritis Care Res*. 2013;65(9):1529-33. **PMCID:PMC3717397**
225. **Solomon DH**, Yelin E, Katz JN, Lu B, Shaykevich T, Ayanian JZ. Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey. *Arthritis Res Ther*. 2013;18;15(2):R43. [Epub ahead of print]. **PMCID:PMC3672709**
226. Suter LG, Paltiel AD, Rome BN, **Solomon DH**, Thornhill TS, Abrams SK, Katz JN, Losina E. "Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty" *PLOS ONE* 2013 May 6,8(5): e62709. **PMCID:PMC3646021**
227. Feldman CH, Hicks LS, Norton TL, Freeman E, **Solomon DH**. Assessing the Need for Improved Access to Rheumatology Care: A Survey of Massachusetts Community Health Center Medical Directors. *J Clin Rheumatol* 2013;10(7):361-6. **PMCID:PMC3840896**
228. Kim SC, Schneeweiss S, Liu J, **Solomon DH**. The Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2013;65(10):1600-7.
229. Yoshida K, Sung Y-K, Kavanaugh A, Bae S-C, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, **Solomon DH**. Biologic discontinuation studies: a systematic review of methods. *Ann Rheum Dis* 2013 May [Epub ahead of print].
230. Mercer E, Norton T, Woo S-B, Treister N, Dodson T, **Solomon DH**. Ninety-one osteoporosis patients affected with bisphosphonate-related osteonecrosis of the jaw: a case series. *Calcif Tissue Int*, 2013;93(3):241-8. **PMCID:PMC3744621**
231. Casey, JD, Vaidya, A, **Solomon, DH**, Gaziano, TA. A Patient with Migrating Polyarthralgias. *N Engl J Med* 2013; 368:(24)e33 doi:10.1056/NEJMimc1209380
232. Kim SC, Landon J, **Solomon DH**. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin or pregabalin. *Arthritis Care Res (Hoboken)*. 2013 June (In press)
233. Everett BM, Pradhan AD, **Solomon DH**, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the

Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. *Am Heart J.* 2013;166(2):199-207 e115. **PMCID:PMC3888829**

234. Diem SJ, Ruppert K, Cauley JA, Lian Y, Bromberger JT, Finkelstein JS, Greendale GA, **Solomon DH**. Rates of bone loss among women initiating antidepressant medication use in mid-life. *J Clin Endocrinol Metab* 2013;96(11):4355-63. **PMCID:PMC3816266**
235. Kim SC, Schmidt B, Franklin J, Liu J, **Solomon DH**, Schneeweiss S. Clinical and health care use characteristics of patients newly prescribed allopurinol, febuxostat and colchicine for gout. *Arthritis Care Res (Hoboken)* 2013;65(12):2008-14. **PMCID:PMC4096791**
236. Schmajuk G, **Solomon, DH**, Yazdany, J. Patterns of disease-modifying anti-rheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review. *Arthritis Care Research (Hoboken)* 2013;65(12):1927-35 .
237. Liao KP, Cai T, Gainer V, Murphy SN, Cagan A, Liu C, Churchill S, Shaw SY, Kohane I, **Solomon DH**, Plenge RM, Karlson EW. Lipid and lipoprotein levels and trends in rheumatoid arthritis compared to the general population. *Arthritis Care Res* 2013;65(12):2046-50. **PMCID:PMC4060244**
238. Gedmintas L, Wright EA, Losina E, Katz JN, **Solomon DH**. Comparative risk of fracture in men and women with HIV. *J Clin Endocrinol Metab* 2014; 99(2):486-90. **PMCID:PMC3913815**
239. Kim SC, Gillet VG, Feldman S, Lii H, Toh S, Brown JS, Katz JN, **Solomon DH**, Schneeweiss S. Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. *Pharmacoepidemiol Drug Saf.* 2013;22(11):1239-44. **PMCID:PMC3855630**
240. **Solomon DH**, Bitton A, Fraenkel L, Brown E, Tsao P, Katz JN. The Roles of Nurse Practitioners and Physician Assistants in Rheumatology Practices in the US. *Arthritis Care Res (Hoboken)* 2014;66(7):1108-1113 **PMCID:PMC4051869**
241. Yelin E, Tonner MC, Kim SY, Katz JN, Ayanian JZ, Brookhart MA, **Solomon DH**. Sociodemographic, disease, health system, and contextual factors affecting the initiation of biological agents in rheumatoid arthritis: a longitudinal study. *Arthritis Care Res (Hoboken)* 2014;66(7):980-9 **PMCID:PMC4124524**
242. Harrold LR, Reed GW, Kremer JM, Curtis JR, **Solomon DH**, Hochberg MC, Greenberg JD. The Comparative Effectiveness of Abatacept versus Anti-Tumor Necrosis Factor Switching for Rheumatoid Arthritis Patients Previously Treated with an Anti-Tumor Necrosis Factor. *Ann Rheum Dis* 2015;74(2):430-6 **PMCID:PMC4316858**
243. Gomez-Puerta JA, Waikar SS, **Solomon DH**, Liu J, Alarcón GS, Winkelmayr WC, Costenbader KH. Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease, *J Clin Cell Immunol*, 2013;4(6):179 **PMCID:PMC3963515**
244. Bykerk VP, Shadick N, Frits M, Bingham CO, Jeffery I, Iannaccone C, Weinblatt M, **Solomon DH**. Flares in Rheumatoid Arthritis: Frequency and Management. A Report from the BRASS Registry. *J Rheumatol* 2014;41:227-34. [Epub]
245. **Solomon DH**, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis Medication Use after Hip Fracture in U.S. Patients between 2002 and 2011. *J Bone Miner Res.* 2014;29(9):1929-37 **PMCID:PMC4258070**

246. **Solomon DH**, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. *Semin Arthritis and Rheum* 2014;43(4): 489-497. [Epub]
247. Kim SC, Liu J, **Solomon DH**. The risk of atrial fibrillation in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2014; 73(6):1091-5. doi: 10.1136/annrheumdis-2013-203343. Epub 2013 Apr 20. **PMCID:PMC3884023**
248. **Solomon DH**, Garg R, Lu B, Todd DJ, Mercer E, Norton T, Massarotti E. The Effect of Hydroxychloroquine on Insulin Sensitivity and Lipid Parameters in Non-Diabetic Patients with Rheumatoid Arthritis: A Randomized Blinded Cross-Over Trial. *Arthritis Care Res (Hoboken)*. 2014;66(8):1246-51 **PMCID:PMC4467535**
249. **Solomon DH**, Tonner C, Lu B, Kim SC, Ayanian JZ, Brookhart MA, Katz JN, Yelin E. Predictors of Stopping and Starting Disease Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2014;66(8):1152-8 **PMCID:PMC4112169**
250. **Solomon DH**, Patrick AR, Schousboe J, Losina E. The Potential Economic Benefits of Improved Post-Fracture Care: A Cost-Effectiveness Analysis of a Fracture Liaison Service in the US Health Care System. *J Bone Miner Res*. 2014;29(7):1667-74 **PMCID:PMC176766**
251. Lu B, **Solomon DH**, Costenbader KH, Karlson EW. Alcohol consumption and risk of incident rheumatoid arthritis in women: A prospective study. *Arthritis Rheum*. 2014;66(8):1998-2005 **PMCID:PMC4116451**
252. Desai SP, Liu C-C, Tory H, Norton T, Frits M, Lillegraven S, Weinblatt M, Coblyn J, Yazdany J, Shadick N, **Solomon DH**. Rheumatoid Arthritis Quality Measures and Radiographic Progression. *Semin Arthritis Rheum*. 2014;44(1):9-13 **PMCID:PMC4111785**
253. Brown EM, Garneau KL, Tsao H, **Solomon DH**. DMARD non-use in low income, elderly rheumatoid arthritis patients: results of 86 structured interviews. *Arthritis Res Ther*. 2014;16(1):R30. **PMCID:PMC3978473**
254. Polinski JM, Brookhart MA, Ayanian JZ, Katz JN, Kim SC, LII J, Tonner C, Yelin E, **Solomon DH**. Relationships between driving distance, rheumatoid arthritis diagnosis, and disease – modifying anti-rheumatic drug receipt. *Arthritis Care Res (Hoboken)*. 2014;66(11):1634-43 **PMCID:PMC4175286**
255. Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, **Solomon DH**. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. *Ann Rheum Dis* 2014;74:1968-75. **PMCID:PMC4263684**
256. Mjaavatten MD, Radner H, Yoshida K, Shadick NA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, **Solomon DH**. Inconsistent treatment with disease-modifying anti-rheumatic drugs: a longitudinal data analysis. *J Rheumatol* 2014;41(12):2370-8 **PMCID:PMC4843119**

257. Liao KP, **Solomon DH**. Mechanistic insights into the link between inflammation and cardiovascular disease: rheumatoid arthritis as a human model of inflammation. *Circ Cardiovasc Imaging* 2014; 7(4):575-7.
258. Gillet VG, **Solomon DH**, Shadick NA, Weinblatt ME, Iannaccone CK, Feldman S, Kim SC, Behavioral and clinical factors associated with self-reported abnormal Papanicolaou tests in rheumatoid arthritis. *J Womens Health (Larchmt)* 2014 ;23(9):7771-6 **PMCID:PMC4158949**
259. Hu Y, Costenbader KH, Gao X, Al-Daabil M, Sparks JA, **Solomon DH**, Hu FB, Karlson EW, Lu B. Sugar-sweetened soda consumption and risk of developing rheumatoid arthritis in women. *Am J Clin Nutr* 2014;100(3):959-67. **PMCID:PMC4135503**
260. Mjaavatten MD, Radner H, Yoshida K, Shadick NA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, **Solomon DH**. Do Rheumatologists Know Best? An Outcomes Study of Inconsistent Users of Disease-Modifying Anti-Rheumatic Drugs. *Semin Arthritis Rheum* 2015;44(4):399-404. **PMCID:PMC4843117**
261. **Solomon DH**, Brown EM, Chandler D, Bower A, Barron R, Mogun H, Franklin JM. Patterns of treatment among a cohort of older low-income adults starting new medications for osteoporosis. *Osteoporos Int*. 2014;25(9):2255-62. doi: 10.1007/s00198-014-2757-7.
262. Kim SC, J Liu, **Solomon DH**. Risk of incident diabetes in patients with gout: a cohort study. *Arthritis Rheumatol* 2015;67(1):273-80. **PMCID:PMC4384181**
263. Desai RJ, Eddings W, Liao KP, **Solomon DH**, Kim SC. Disease modifying anti-rheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis. *Arthritis Care Res* 2014;67(4):457-66. **PMCID:PMC4751079**
264. MacFarlane L, Chih-Chin L, **Solomon DH**. Effect of Initiating Pharmacologic Insulin on Serum Uric Acid Levels in Patients with Diabetes: A Matched Cohort Analysis. *Semin Arthritis Rheum* 2015;44(5):592-6 **PMCID:PMC4390413**
265. Tory HO, **Solomon DH**, Desai SP. Analysis of quality improvement efforts in preventing glucocorticoid induced osteoporosis. *Seminars in Arthritis and Rheumatism*. 2015;44(5):483-8.
266. Wright EA, Katz JN, Abrams S, **Solomon DH**, Losina E. Trends in prescription of opioids from 2003-2009 in persons with knee osteoarthritis. *Arthritis Care Res (Hoboken)* 2014;66:1489-1495. **PMCID:PMC4177407**
267. Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, Etzel CJ, Cox V, Yoshida K, Reed GW, **Solomon DH** Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. *Ann Rheum Dis*. 2015 Jun;74(6):1150-5. doi: 10.1136/annrheumdis-2014-206435.
268. Kim SC, **Solomon DH**, Liu J, Franklin JM, Glynn RJ, Schneeweiss S Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis Initiating Disease-Modifying Antirheumatic Drugs.. *Am J Med*. 2015;128(5):539. **PMCID:PMC4414700**
269. **Solomon DH**, Reed G, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, Hochberg MC, Tsao P, Greenberg J. Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events. *Arthritis Rheumatol*. 2015;67(6):1449-55. **PMCID:PMC4446181**

270. Kim SC, **Solomon DH**, J Liu, JM Franklin, RJ Glynn, S Schneeweiss. Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis Initiating Disease-Modifying Am J Med. 2015;128(5):539. **PMCID:PMC4414700**
271. Kim SC, Schneeweiss S, Choudhry N, Glynn RJ, **Solomon DH** Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015;128(6):653. **PMCID:PMC4442710**
272. **Solomon, DH**, Greenberg J, Curtis JR, Liu M, Farkouh ME, Tsao P, Kremer JM, Etzel CJ. Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA): A CORRONA Registry Study. Arthritis Rheumatol 2015;67(8):1995-2003.
273. Kim DH, Roger JR, Fulchino LA, Kim CA, **Solomon DH**, Kim SC. Bisphosphonates and Adverse Cardiovascular Events: A Meta-Analysis. PLOS One. 2015;10(4) e0122646. doi.org/10.1371/journal.pone.0122646 **PMCID:PMC4401508**
274. Kesselheim AS, Franklin JM, Kim SC, Seeger JD, **Solomon DH**. Reductions in use of colchicine after FDA enforcement of market exclusivity in a commercially insured population. J Gen Intern Med 2015;30(11):1633-8. **PMCID:PMC4617917**
275. Desai RJ, **Solomon DH**, Weinblatt M, Shadick N, Kim SC. An External Validation Study Reporting Poor Correlation Between the Claims Based Index for Rheumatoid Arthritis Severity and the Disease Activity Score. Arthritis Res & Ther 2015;17:83. **PMCID:PMC4394559**
276. Yoshida K, Kishimoto M, Radner H, Matsui K, Okada M, Saeki Y, **Solomon DH**, Tohma S. Low Rates of Biological-free DCAI Remission Maintenance after Biological DMARD Discontinuation while in Remission in a Japanese Multi-center RA Registry. Rheumatology (Oxford) 2015;55(2):286-90 **PMCID:PMC4751227**
277. Tory HO, **Solomon DH**, Desai SP. Analysis of quality improvement efforts in preventing glucocorticoid-induced osteoporosis. Semin Arthritis Rheum 2015;44(5):483-488.
278. Desai RJ, **Solomon DH**, Schneeweiss S, Danaei G, Liao K, Kim SC. Tumor necrosis factor- α inhibitor use and the risk of incident hypertension in patients with rheumatoid arthritis: A retrospective cohort study. Epidemiology 2016;27(3):414-22.
279. Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanagh A, Kishimoto M, Matsui K, Okada M, Reed G, Saeki Y, Tohma S, Kremer JM, **Solomon DH**. Incidence and predictors of biological antirheumatic drug discontinuation attempts among rheumatoid arthritis patients in remission: a Corrona and NinJa collaborative cohort study. J Rheumatol 2015;42(12):2238-46
280. Radner H, Yoshida K, Frits M, Iannaccone C, Shadick NA, Weinblatt M, Smolen JS, **Solomon DH**. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2015;54(11):2076-84.
281. Radner H, Yoshida K, Hmamouchi I, Dougados M, Smolen JS, **Solomon DH**. Treatment patterns of multimorbid patients with rheumatoid arthritis: results from an international cross-sectional study. J Rheumatol 2015;42(7):1099-1104.
282. Radner H, Yoshida K, Mjaavatten MD, Aletaha D, Frits M, Lu B, Iannaccone C, shadick NA, Weinblatt ME, Hmamouchi I, Dougados M, Smolen JS, **Solomon DH**. Development of a

multimorbidity index: impact on quality of life using a rheumatoid arthritis cohort. *Semin Arthritis Rheum* 2015;45(2):167-73.

283. **Solomon DH**, Patrick AR, Schousboe J, Losina E,. The Potential Economic Benefits of Improved Postfracture Care: A Cost-Effectiveness Analysis of a Fracture Liaison Service in the US Health-Care System. *J Bone Miner Res* 2014;29(7):1667-1674 **PMCID:PMC4176766**
284. **DH Solomon**, L Fraenkel, B Lu, E Brown, P Tsao, E Losina, JN Katz, A Bitton. A Comparison of Care Provided in Practices with Nurse Practitioners and Physicians Assistants versus Sub-Specialist Physicians Only: A Cohort Study of Rheumatoid Arthritis. *Arthritis Research Care* 2015;67(12):1664-70 **PMCID:PMC4684815**
285. Kim SC, J Liu, **DH Solomon**. Risk of incident atrial fibrillation in gout: a cohort study. *Ann Rheum Dis* 2015;75:1473-78. **PMCID:PMC4775439**
286. Lee YC, Massarotti E, Edwards RR, Lu B, Liu C, Lo Y, Wohlfahrt A, Kim ND, Clauw DJ, **Solomon DH**. The effect of milnacipran on pain in rheumatoid arthritis patients with widespread pain: a randomized blinded crossover trial. *J Rheumatol* 2015;43(1):38-45 **PMCID:PMC4698221**
287. **DH Solomon**, K Ruppert, Z Zhao, Y Lian, I-H Kuo, GA Greendale, JS Finkelstein. Bone Mineral Density Changes Among Women Initiating Blood Pressure Lowering Drugs: A SWAN Cohort Study. *Osteoporosis Int* 2016;27(3):1181-9 **PMCID:PMC4813302**
288. Duryea J, Russell R, Gravallese EM, Kay J, Han R, Lu B, **Solomon DH**. Development and Validation of a Semi-Automated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. *Arthritis Rheumatol* 2016;68(2):332-36.
289. Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, **Solomon DH**, Costenbader KH, Karlson EW. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: Results from the Nurses' Health Study. *Arthritis Care Res.* 2016;68(6):753-62 **PMCID:PMC4944846**
290. Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Molken MPMH, Liao KP, Solomon DH. Cardiovascular Risk Factor Management in Patients with RA Compared to Matched Non-RA Patients. *Rheumatology (Oxford)* 2016;55(5):809-16 **PMCID:PMC4830910**
291. **Solomon DH**, Liu CC, Kuo IH, Zak A, Kim SC. The Effects of Colchicine on Risk of Cardiovascular Events and Mortality Among Patients with Gout: A Cohort Study Using Electronic Medical Records Linked with Medicare Claims. *Ann Rheum Dis* 2016;75(9):1674-9 **PMCID:PMC5049504**
292. SC Kim, N-K Choi, J Lee, K-E Kwon, W Eddings, Y-K Sung, HJ Song, AS Kesselheim, **DH Solomon**. Brief Report: Utilization of the First Biosimilar Infliximab since its Approval in South Korea. *Arthritis Rheumatol.* 2016;68(5):1076-9 **PMCID:PMC4848142**
293. **DH Solomon**, SJ Diem, K Ruppert, YJ Lian, C-C Liu, A Wohlfahrt, GA Greendale, JS Finkelstein. Bone Mineral Density Changes Among Women Initiating Proton Pump Inhibitors or H2 Receptor Antagonists: A SWAN Cohort Study. *J Bone Miner Res* 2015;30(2):232-9 **PMCID:PMC4404624**
294. Katz JN, Smith SR, Collins JE, **Solomon DH**, Jordan JM, Hunter DJ, Paltiel, AD, Losina E. Cost-effectiveness of nonsteroidals anti-inflammatory drugs and opioids in the treatment of knee

osteoarthritis in older patients with multiple comorbidities. *Osteoarthritis Cartilage* 2016;24(3):409-18 **PMCID:PMC4761310**

295. An J, Cheetham TC, Reynolds K, Alemao E, Kawabata H, Liao KP, **Solomon DH**. Traditional Cardiovascular Risk Factor Management in Rheumatoid Arthritis Compared to Matched Non-Rheumatoid Arthritis in a US Managed Care Setting. *Arthritis Care Res (Hoboken)* 2016;68(5):629-37.
296. Desai RJ, **Solomon DH**, Shadick NA, Iannaccone CK, Kim SC. Identification of smoking using Medicare data- A validation study of claims-based algorithms. *Pharmacoepidemiol Drug Saf.* 2016;25(4):472-5 **PMCID:PMC4826837**
297. **Solomon DH**, Ruppert K, Greendale GA, Lian Y, Selzer F, Finkelstein JS. Medication Use by Race and Ethnicity in Women Transitioning Through the Menopause: A SWAN Drug Epidemiology Study. *J Women's Health.* 2016;25(6):599-605 **PMCID:PMC4900213**
298. Seton M, Hansen H, **Solomon DH**. The Implications of the Sequestosome 1 Mutation P392L in Patients with Paget's Disease in a United States Cohort. *Calc Tissue Int* 2016;98(5):489-96 **PMCID:PMC4847721**
299. **Solomon DH**, Lee SB, Zak A, Corrigan C, Agosti J, Bitton A, Harrold L, Losina E, Lu B, Pincus T, Radner H, Smolen J, Katz JN, Fraenkel L. Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Rationale and Design of the TRACTION Trial. *Semin Arthritis Rheum* 2016;46(1):81-7 **PMCID:PMC4969092**
300. SC Kim, S Schneeweiss, J Liu, EW Karlson, JN Katz, S Feldman, **DH Solomon**. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: a Cohort Study. *Arthritis Rheumatol* 2016;68(9):2106-13 **PMCID:PMC5001884**
301. Deshpande BR, Katz JN, **Solomon DH**, Yelin EH, Hunter DJ, Messier SP, Suter LG, Losina E. The number of persons with symptomatic knee osteoarthritis in the United States: Impact of race/ethnicity, age, sex, and obesity. *Arthritis Care Res.* 2016;68(12):1743-1750 **PMCID:PMC5319385**
302. Harrold L, Reed G, Kremer J, Curtis J, **Solomon D**, Hochberg M, Kavanaugh A, Saunders K, Shan Y, Spruill T, Pappas D, Greenberg J. Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. *Arthritis Research & Therapy.* 2016;18(1):94 **PMCID:PMC4845312**
303. Cisternas MG, Murphy L, Sacks JJ, **Solomon DH**, Pasta DJ, Helmick CH. Alternative Methods for Defining Osteoarthritis and the Impact on Estimating Prevalence in a US Population-Based Survey. *Arthritis Care Res (Hoboken)* 2016;68(5):574-580 **PMCID:PMC4769961**
304. Gedmintas L, Wright EA, Dong Y, Lehmann E, Katz JN, **Solomon DH**, Losina E. Factors associated with fractures in HIV-infected persons: which factors matter? *Osteoporosis Int* 2017;28(1):239-244.
305. Sparks JA, Krumme AA, Shrank WH, Matlin OS, Brill G, Pezalla EJ, Choudhry NK, **Solomon DH**. Intensification to triple therapy non-biologic disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States from 2009 to 2014. *Arthritis Rheumatol.* 2016;68(7):1588-1595. **PMCID:PMC5068482**
306. Danila MI, Outman RC, Rahn EJ, Mudano AS, Thomas TF, Redden DT, Allison JJ, Anderson FA, Anderson JP, Cram PM, Curtis JR, Fraenkel L, Greenspan SL, LaCroix Z, Majumdar SR, Miller MJ, Nieves JW, Safford MM, Silverman SL, Siris ES, **Solomon DH**, Warriner A H, Watts NB, Yood RA., Saag KG A Multi-modal intervention for activating patients at risk for osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention

material. Contemporary Clinical Trial Communications. Contemp Clin Trials Commun 2016;4:14-24 **PMCID:PMC4955389**

307. MacFarlane LA, Liu CC, **Solomon DH**, Kim SC. Validation of claims-based algorithms for gout flares. *Pharmacoepidemiol Drug Saf.* 2016;25(7):820-6 **PMCID:PMC4930384**
308. Yoshida K, Hernández-Díaz S, **Solomon DH**, Jackson JW, Gagne JJ, Glynn RJ, Franklin JM. Matching weights to simultaneously compare three treatment groups: Comparison to three-way matching. *Epidemiology* 2017;28(3):387-395 **PMCID:PMC5378668**
309. Choudhry NK, Isaac T, Lauffenburger JC, Gopalakrishnan C, Khan NF, Lee M, Vachon A, Iliadis TL, Hollands W, Doheny S, Elman S, Kraft JM, Naseem S, Gagne JJ, Jackevicius CA, Fischer MA, **Solomon DH**, Sequist TD. Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster randomized pragmatic trial. *American Heart J* 2016;180:90-7. **PMCID:PMC5053099**
310. Kim SC, Paik JM, Liu J, Curhan GC, **Solomon DH**, Gout and the Risk of Non-vertebral Fracture. *J Bone Miner Res* 2017;32(2):230-236. **PMCID:PMC5292077**
311. Feldman CH, Liu J, Feldman S, **Solomon DH**, Kim, SC. Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus Receiving Immunosuppressive Drugs. *Lupus* 2017;26:682-689. **PMCID:PMC5397330**
312. Choi N-K, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC. Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: A cohort study. *J Bone Miner Res* 2017;32(3):611-617. **PMCID:PMC5340628**
313. Harrold LR, Reed GW, **Solomon DH**, Curtis JR, Liu M, Greenberg JD, Kremer J. Comparative Effectiveness of Abatacept versus Tocilizumab in Rheumatoid Arthritis Patients with Prior TNFi Exposure in the United States Corona registry. *Arthritis Res Ther* 2016;18(1):280. **PMCID:PMC5134270**
314. Desai RJ, Solomon DH. Use of large healthcare databases for rheumatology clinical research. *Curr Opin Rheumatol* 2017;29(2):138-143.
315. Radner H, Yoshida K, Tedeschi S, Studenic P, Frits M, Iannaccone C, Shadick NA, Weinblatt M, Aletaha D, Smolen JS, Solomon DH. Different Rating of Global Rheumatoid Arthritis (RA) Disease Activity in Multimorbid Patients with RA. *Arthritis Rheumatol.* 2017;69(4):720-727.
316. Lee SB, Zak A, Iversen MD, Polletta VL, Shadick NA, **Solomon DH**. Participation in clinical research registries: a focus group study examining views from patients with arthritis and other chronic illnesses. *Arthritis Care Res (Hoboken)* 2016;68(7):974-80.
317. Radner H, Lesperance T, Accortt NA, **Solomon DH**. Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. *Arthritis Care Res (Hoboken)* 2017;69:1510-18.
318. Jackson EA, Ruppert K, Derby CA, Lian Y, Neal-Perry G, Habel L, Tepper PG, Harlow SD, **Solomon DH**. The Effect of Race and Ethnicity on Antihypertensive Medication Utilization among Women in the United States: The Study of Women's Health Across the Nation (SWAN). Accepted, *Journal of the American Heart Association.*, 2017;23:6(3) doi:10.1161/JAHA.116.004758
319. Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, **Solomon DH**, Costenbader KH, Kim SC. Comparative Rates of Serious Infections among Patients with Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. *Arthritis Rheumatol.* 2017;69(2): 387-397 **PMCID:PMC5274610**
320. Sparks JA*, Barbhaiya M*, Karlson EW, Ritter SY, Raychaudhuri S, Corrigan C, Lu F, Selhub J, Chasman DI, Paynter NP, Ridker PM, **Solomon DH**. Investigating methotrexate toxicity within a

randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial Adverse Events (CIRT-AE) Study. *Semin Arthritis Rheum*. 2017 Feb 10 doi:10.1016/j.semarthrit [Epub ahead of print]

321. Tedeschi SK, Frits M, Cui J, Zhang ZZ, Mahmoud T, Iannaccone C, Lin T-C, Yoshida K, Weinblatt ME, Shadick NA, **Solomon DH**. Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. *Arthritis Care & Research*. 2017 Feb 19. Doi:10.1002/acr.23225.
322. T-C Lin, N Hashemi, SC Kim, Y-H Lao Yang, K Yoshida, S Tedeschi, R Desai, **DH Solomon**. The Practice Pattern of Hepatitis B Testing in rheumatoid Arthritis Patients; a Cross National Comparison between the US and Taiwan. *Arthritis Care & Res*. 2017 [Epub ahead of print]
323. **Solomon DH**, E Losina, B Lu, A Zak, C Corrigan, SB Lee, J Agosti, A Bitton, LR Harrold, T Pincus, H Radner, Z Yu, JS Smolen, L Fraenkel, JN Katz. Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Results of the TRACTION Randomized Controlled Trial. *Arthritis Rheumatol* 2017;69:1374-80.
324. Kim SC, **Solomon DH**, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. Cardiovascular Safety of Tocilizumab versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis-a Multi database Cohort Study. *Arthritis Rheumatol* 2017;69:1154-64.
325. Barbhaiya M, Feldman CH, Guan H, Gomez-Puerta JA, Fischer MA, **Solomon DH**, Everett B, Costenbader KH. Race/Ethnicity and Cardiovascular Events among Patients with Systemic Lupus Erythematosus. *Arthritis Rheum*. 2017 Jun 9. Doi:10.1002/art.40174.
326. Franklin JM, Schneeweiss S, **Solomon DH**. Assessment of confounders in comparative effectiveness studies from secondary databases. *Am J Epidemiol* 2017;185:474-478.
327. **Solomon DH**, NA Shadick, ME Weinblatt, M Frits, C Iannaccone, A Zak, JR Korzenik. Clinical Patient Registry Recruitment and Retention: A Survey of Patients in Two Chronic Disease Registries. *BMC Medical Research Methodology* 2017;17:59.
328. **Solomon DH**, NA Shadick, ME Weinblatt, A Zak, M Frits, J Franklin. Drug Safety Analyses in a Rheumatoid Arthritis Registry: Application of Different Approaches Regarding Timing of Exposure and Confounder Measurement. *Arthritis Research & Therapy* 2017;19:130.
329. **Solomon DH**, J Kay, J Duryea, B Lu, MB Bolster, RA Yood, R Han, S Ball, C Coleman, E Lo, A Wohlfahrt, M Sury, M Yin, Z Yu, A Zak, EM Gravallese. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. *Arthritis Rheumatol* 2017 May 23. doi: 10.1002/art.40156.
330. Tedeschi SK, Bathon JM, Giles JT, Lin T-C, Yoshida K, **Solomon DH**. The relationship between fish consumption and disease activity in rheumatoid arthritis. *Arthritis Care & Research* 2017 Jun 21. doi: 10.1002/acr.23295.
331. Shadick NA, Zibit MJ, Iannaccone CI, Thrower R, Sowell NF, Weinblatt ME, **Solomon DH**, Cui J. A Development and Feasibility Study of a Peer Support Telephone Program in Rheumatoid Arthritis. *J Clin Rheum*. In press 2017
332. Feldman CH, Wohlfahrt A, Campos A, Gagne JJ, Iversen M, Massarotti E, **Solomon DH**, Kawachi I. Can Patient Navigators Improve Adherence to Disease-Modifying Antirheumatic Drugs? Quantitative Findings from the Med Assist Pilot Study. *Arthritis Care Res (Hoboken)*. 2017 Jun 02. PMID: 28575545.
333. Lee MP, Lii J, Jin Y, Desai RJ, **Solomon DH**, Merola JF, Kim SC. Patterns of Systemic Treatment for Psoriatic Arthritis in the United States: 2004-2015. *Arthritis Care Res*. 2017 Aug 13. PMID: 28804988.

334. Lin TC, Yoshida K, Tedeschi SK, Abreu MMD, **Solomon DH**. Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): A Systematic Review and Meta-Analysis. *Arthritis Care & Research* 2017 (in press)
335. Yu, Z., Lu, B., Agosti, J., Bitton, A., Corrigan, C., Fraenkel, L., Harrold LR, Losina E, Katz, JN, **Solomon, DH**. (2017). Implementation of Treat to Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data from the TRACTION Trial. *Arthritis Care Res (Hoboken)*. doi:10.1002/acr.23343.
336. Lin TC, **Solomon DH**, Tedeschi SK, Yoshida K, Kao Yang YH. Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Non-Selective NSAIDs in Taiwanese Rheumatoid Arthritis Patients. *Journal of American Heart Association* 2017 (in press).
337. Ruppert K, Cauley J, Lian Y, Zgibor JC, Derby C, **Solomon DH**. The effect of insulin on bone mineral density among women with type 2 diabetes: a SWAN Pharmacoepidemiology study. *Osteoporosis International* 2017 (E-pub ahead of print, October 30, 2017).
338. Paik JM, Kim SC, Feskanich D, Choi HK, **Solomon DH**, Curhan GC. Gout and Risk of Fracture in Women: A Prospective Cohort Study. *Arthritis Rheumatol*. 2017 Feb;69(2):422-428. doi: 10.1002/art.39852. PMID 27589491. PMCID: PMC5274565.
339. Abreu MMD, Maiorano AC, Tedeschi SK, Yoshida K, Lin TC, **Solomon DH**. Outcomes of Lupus and Rheumatoid Arthritis Patients with Primary Dengue Infection: A Seven Year Report from Brazil. *Semin Arthritis Rheum* 2017 (epub ahead of print, September 2017). PMID 29061443.
340. Yoshida K, Yu Z, Greendale GA, Ruppert K, Lian Y, Tedeschi SK, Lin TC, Haneuse S, Glynn RJ, Hernandez-Diaz S, **Solomon DH**. Effects of Analgesics on Bone Mineral Density: a Longitudinal Analysis of the Prospective SWAN Cohort with Three-group Matching Weights. *Pharmacoepidemiol Drug Saf* 2017 (In press).
341. **DH Solomon**, ME Husni, KE Wolski, LM Wisniewski, JS Borer, DY Graham, P Libby, AM Lincoff, TF Lüscher, V Menon, ND Yeomans, Q Wang, W Bao, MF Berger, SE Nissen M.D. on behalf of the PRECISION Trial Investigators Differences in Safety of Non-Steroidal Anti-Inflammatory Drugs in Patients with Osteoarthritis versus Rheumatoid Arthritis: a Randomized Clinical Trial. *Arthritis Rheumatol*, In Press 2017.
342. Lee YC, Karlamangla AS, Yu Z, Liu CC, Finkelstein JS, Greendale JA, Harlow SD, **Solomon DH**. Pain severity in relation to the final menstrual period in a prospective multiethnic observational cohort: Results from the Study of Women's Health Across the Nation (SWAN). *J Pain*. 2017; 18:178-87. PMCID:PMC5291798
343. **Solomon DH**, Lu B, Yu Z, Corrigan C, Harrold LR, Smolen JS, Fraenkel L, Katz JN, Losina, E. Benefits and Sustainability of a Learning Collaborative for Implementation of Treat to Target in Rheumatoid Arthritis: Results of TRACTION Phase II. *Arthritis Care Research*, In Press 2017.
344. Kim SC, Neogi T, Kang EH, Liu J, Desai R, Zhang M, **Solomon DH**. Cardiovascular Risks of Probenecid versus Allopurinol in Older Patients with Gout. *J Am Coll Cardiol* 2018;71:994-1004.
345. Hresko A, Lin J, **Solomon DH**. Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-analysis. *Arthritis Care Research* 2017, In press.
346. Feldman CH, Collins J, Zhang Z, Subramanian SV, **Solomon DH**, Kawachi I, Costenbader KH. Dynamic Patterns and Predictors of Hydroxychloroquine Nonadherence among Medicaid Beneficiaries with Systemic Lupus Erythematosus. *Semin Arthritis Rheum*. Accepted Jan 2, 2018 [In Press].
347. Kim SC, Shah NR, Rogers JR, Bibbo CF, Di Carli MF, **Solomon DH**. Assessment of coronary vascular function with cardiac PET in relation to serum uric acid. *PLOS One*. 2018 January [in press]

348. Desai RJ, Franklin JM, Spoenclin-Allen J, **Solomon DH**, Danaei G, Kim SC. An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. *PLoS One*. 2018 Feb 28;13(2):e0193622. doi: 10.1371/journal.pone.0193622. eCollection 2018. PubMed PMID: 29489919.
349. **Solomon DH**, Libby P, Yeomans ND, Wang Q, Wolski KE, Nissen SE, Husni ME. The Potential Benefits of Aspirin for Primary Cardiovascular Prevention in Rheumatoid Arthritis: A Secondary Analysis of the PRECISION Trial. *Rheumatology* 2018, In Press.
350. Kim SC, **Solomon DH**, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. No Difference in Cardiovascular Risk of Tocilizumab versus Abatacept for Rheumatoid Arthritis: a Multi-database Cohort Study. *Semin Arthritis Rheum*. 2018 March [in press]
351. Yu Z, Yang N, Everett BM, Frits M, Iannaccone C, Coblyn J, Weinblatt M, Shadick N, **Solomon DH**, Liao KP. Impact of changes in inflammation on estimated cardiovascular risk in rheumatoid arthritis. *Arthritis & Rheumatology (Hoboken, NJ)*. 2018 (in press)
352. Reed GW, Abdallah MS, Shao M, Wolski K, Wisniewski L, Yeoman N, Luscher TF, Borer JS, Graham DY, Husni ME, **Solomon DH**, Libby P, Menon V, Lincoff AM, Nissen SE. Effect of aspirin co-administration on the safety of celecoxib, naproxen, or ibuprofen. *J Am Coll Cardiol* 2018;71:1741-51.
353. Zak A*, Corrigan C*, Yu Z, Bitton A, Fraenkel L, Harrold L, Smolen JS, **Solomon DH**. Barriers to Treatment Adjustment within a Treat to Target Strategy in Rheumatoid Arthritis: A Secondary Analysis of the TRACTION Trial. *Rheumatology*, In Press, 2018.
354. Sparks JA, Lesperance T, Accortt NA, **Solomon DH**. Subsequent cardiovascular events among patients with rheumatoid arthritis, psoriatic arthritis, or psoriasis: Patterns of disease-modifying antirheumatic drug treatment. *Arthritis Care Res*. 2018 (In Press).
355. Choudhry NK, Isaac T, Lauffenburger JC, Gopalakrishnan C, Lee M, Vachon A, Iliadis TL, Hollands W, Elman S, Kraft JM, Naseem S, Doheny S, Lee J, Barberio J, Patel L, Khan NF, Gagne JJ, Jackevicius CA, Fischer MA, **Solomon DH**, Sequist TD. Effect of a remotely-delivered tailored multicomponent approach to enhance medication-taking for patients with cardiometabolic conditions: The STIC2IT cluster randomized clinical trial. *JAMA Internal Medicine* 2018; in press.
356. Zhang MN, **Solomon DH**, Desai RJ, Kang EH, Liu J, Neogi T, Kim SC. Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: a Population-based Cohort Study. *Circulation* 2018 May; 118.033992. doi: 10.1161/CIRCULATIONAHA.118.033992.
357. Yu Z, Kim SC, Vanni K, Huang J, Desai R, Murphy SN, **Solomon DH**, Liao KP. Association between inflammation and systolic blood pressure in RA compared to patients without RA. *Arthritis research & therapy*. 2018;20:107.
358. Ogdie, A, Palmer JL, Greenberg J, Curtis JR, Harrold, LR, **Solomon, DH**, Kavanaugh, A, Kremer, JM, Mease, P. Predictors of achieving remission among patients with psoriatic arthritis initiating a TNF inhibitor. *J Rheumatol* 2018; In Press.
359. Kim SC, Di Carli MF, Garg RK, Vanni K, Wang P, Wohlfahrt A, Yu Z, Lu F, Campos A, Bibbo CF, Smith S, **Solomon DH**. Asymptomatic hyperuricemia and coronary flow reserve in patients with metabolic syndrome. *BMC Rheumatology*. 2018 2:17 <https://doi.org/10.1186/s41927-018-0027-6>
360. Wohlfahrt A, Campos A, Iversen MD, Gagne JJ, Massarotti E, **Solomon DH**, Feldman C.H. Use of Rheumatology-Specific Patient Navigators to Understand and Reduce Barriers to Medication Adherence: Analysis of Qualitative Findings. *PLOS ONE*. Accepted July 12, 2018. In press.

361. Feldman CH, Costenbader KH, **Solomon DH**, Subramanian SV, Kawachi I. Area-level Predictors of Medication Nonadherence among U.S. Medicaid Beneficiaries with Lupus: A Multilevel Study. *Arthritis Care Res (Hoboken)*. [In Press]
362. **Solomon DH**, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, Ridker PM. Relationship of IL-1 Blockade With Incident Gout and Serum Urate Levels: Exploratory Analysis of a Randomized Controlled Trial. *Annals Intern Med*, In Press.

Other Peer Reviewed Publications (Reviews, Chapters, Editorials)

1. **Solomon DH**, Gurwitz J. Toxicity of non-steroidal anti-inflammatory drugs in the elderly: Is advanced age a risk factor? *Am J Med* 1997;102:208-15.
2. **Solomon DH**, Bates DW, Panush R, Katz JN. Costs, outcomes and patient satisfaction with rheumatic and musculoskeletal conditions: A critical review of the literature and proposed methodologic standards. *Ann Intern Med* 1997;127:52-60.
3. Katz JN, **Solomon DH**, Bates DW. Differences between generalists and specialists. *Arthritis Rheum* 1997;10:161-2.
4. **Solomon DH**, Liang MH. Fibromyalgia: Scourge of humankind or the bane of a rheumatologist's existence. *Arthritis Rheum* 1997;40:1553-4.
5. **Solomon DH**, Hashimoto H, Daltroy L, Liang MH. Techniques to improve physicians' use of diagnostic tests: A new conceptual framework and critical review of the literature. *JAMA* 1998;280:2020-7.
6. **Solomon DH**, Liang MH. Specialists under siege. *J Clin Rheumatol* 1998;4:112-3.
7. **Solomon DH**, Helfgott SM. Systemic Vasculitis. In Badey PP, Buttaro TM, Oas KH, Trybulski J, Editors. *Primary Care: A Collaborative Practice*. St. Louis (MO): Mosby; 1998.
8. Kavanaugh A, Tomar R, Reveille J, **Solomon DH**, Homburger HA. Guidelines for clinical use of the ANA test and tests for specific autoantibodies to nuclear antigens. *Arch Path Lab Med* 2000;124:71-81.
9. Avorn J, **Solomon DH**. Cultural and economic factors that (mis)shape antibiotic utilization: The non-pharmacologic basis of therapeutics. *Ann Intern Med* 2000;133:128-35.
10. Schaffer JL, Gard PJ, **Solomon DH**. Arthritis of the Knee. In *Orthopaedics*, Editors Fitzgerald RH, Kaufer H, Malkani AL. St Louis (MO): Mosby; 2002.
11. **Solomon DH**, Katz JN. Generalist, specialist, or both? *J Rheumatol* 2002;29:1345-7.
12. Kavanaugh AF, **Solomon DH**, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. *Arthritis Rheum* 2002;47:429-33.
13. **Solomon DH**, Kavanaugh AF, Schur P. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. A report from the ACR Ad Hoc Committee on Immunologic Testing Guidelines. *Arthritis Rheum* 2002;47:434-4.

14. Husni ME, **Solomon DH**, Coblyn JS. Selective COX-2 inhibitors: towards defining their appropriate clinical role. *J Clin Outcomes Manage* 2002;9:265-68.
15. Reveille JD, **Solomon DH**, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic laboratory tests: anti-centromere, Scl-70, and nucleolar antibodies. *Arthritis Rheum* 2003;49:399-412.
16. Ray WA, MacDonald TM, **Solomon DH**, Graham DJ, Avorn J. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. *Pharmacoepidemiology & Drug Safety* 2003;12:67-70.
17. Kim S, Losina E, **Solomon DH**, Wright J, Katz JN. Effectiveness of clinical pathways for total knee and total hip replacement. *J Arthroplasty* 2003;18:69-74.
18. Bischoff H, **Solomon DH**. Managing fractures and osteoporosis in patients with rheumatoid arthritis. *J Musculoskeletal Med* 2003;October:475-84.
19. **Solomon DH**, Avorn J. Pharmacoepidemiology and rheumatic diseases: 2001-2002. *Current Opinion Rheumatology* 2003;15:1220-6.
20. MacLean CH, Saag KG, **Solomon DH**, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's Quality Indicator Set. *Arthritis Rheum* 2004;51:193-202.
21. Morris CM, Cabral D, Cheng H, Katz JN, Finkelstein JS, Avorn J, **Solomon DH**. Patterns of screening for osteoporosis: a structured review of the literature. *J Gen Intern Med* 2004;19:783-790. **PMCID: PMC1492483**
22. Morris CM, Cheng H, Cabral D, **Solomon DH**. Predictors of Osteoporosis Management. *Endocrinologist*. 2004;14:70-5.
23. **Solomon DH**, Maetzel A. Pharmacoeconomics of prescribing for rheumatoid arthritis. *Int J Adv Rheumatol* 2004.
24. **Solomon DH**, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, Avorn J. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. *Mayo Clinic Proc* 2005;80:194-202.
25. **Solomon DH**, Avorn J. Coxibs, science, and the public trust. *Arch Intern Med* 2005;158-160.
26. Katz JN, Costenbader K, **Solomon DH**, Losina E. Does practice make perfect? *Arthritis Rheum* 2005;52:1628-31.
27. **Solomon DH**. Selective COX-2 inhibitors and cardiovascular outcomes. *Arthritis Rheum* 2005;52:1968-78.
28. **Solomon DH**, Goodson N. Cardiovascular disease. The new extra-articular manifestation? *J Rheumatol* 2005;32:1415-8.
29. Goodson NJ, **Solomon DH**. The cardiovascular manifestations of rheumatic disease. *Curr Opinion Rheumatol* 2006;18:135-40.

30. Goodson NJ, **Solomon DH**. Cardiovascular disease in Rheumatology. In: Topol Textbook of Cardiovascular Medicine. York PA: Tech Books; 2006.
31. ACR Subcommittee on Classification and Response Criteria (Singh J (co-chair), **Solomon DH** (co-chair), Felson D, Hawker G, Katz P, Paulus H, Wallace C). Development of classification and response criteria for rheumatic diseases. *Arthritis Rheum (Arthritis Care & Research)* 2006;55:348-52.
32. **Solomon DH**. COX-2 selective inhibitors: adverse cardiovascular events. In: UpToDate. Waltham MA, 2007.
33. **Solomon DH**. The comparative safety and effectiveness of TNF alpha antagonists in adult rheumatoid arthritis. *J Manag Care Pharm* 2007;13:S7-S18.
34. **Solomon DH**. Commentary on the recent paper by Kearney et al on COX2 inhibitors and the risk of atherothrombosis. *Nat Clin Practice Rheumatol* 2006;2:586-7.
35. Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT, Hawker, GA, Singh JA, **Solomon DH**. Classification Criteria in the Rheumatic Diseases:A Review of Methodologic Properties. *Arthritis Rheum.* 2007;57:1119-33.
36. Woo SB, **Solomon DH**. Bisphosphonate therapy for cancer and prevalence of jaw conditions. *J Nat Cancer Inst* 2007;99:1-2.
37. **Solomon DH**, Gabriel SE. Quality measures 101: what every rheumatologist should know. *Clin Exp Rheumatol* 2007;25(Suppl 47): S18 – S21.
38. **Solomon DH**, Bates DW, Katz JN, Simel DL, Schaffer JL. Does this patient have a “mechanical” knee problem? The value of the physical examination in determining whether a patient has a meniscal or ligamentous injury. In: Simel DL and Rennie D, eds. *JAMA Rational Clinical Examination*. New York:McGraw-Hill; 2008.
39. **Solomon DH**. Determining the best treatments for the right people in rheumatology. *Current Opinion Rheumatology* 2008;20:121-22.
40. Love T, **Solomon DH**. Malignancy in rheumatoid arthritis: not yet a settled question. *Arthritis Res Therapy* 2008;10:R45.
41. **Solomon DH**. Will absolute fracture risk prediction facilitate treatment of osteoporosis? (Commentary on Hans et al.) *Nat Clin Practice Endocrinol* 2008;4:480-481.
42. **Solomon DH**, Kavanaugh A. Pharmacoeconomic aspects of rheumatoid arthritis management. *Rheumatology*. Editors: Hochberg M, Silman A, Smolen J, Weinblatt ME, Weismann M. Lippincott, USA. 2009.
43. **Solomon DH**, Tyndall A, Gabriel SE, Dougados M. Rheumatology gone global. *Ann Rheum Disease* 2008;67:1357. (published simultaneously in *Arthritis Rheum*) *Arthritis Rheum.* 2008;59:1369-70.
44. **Solomon DH**, Kavanaugh A. The economics of rheumatoid arthritis management. *Int J Advances in Rheumatol* 2008;6:2-5.

45. **Solomon DH.** Clinical research In rheumatology: many promises and several disappointments. *Current Opinions Rheumatology* 2009;21:93-4
46. **Solomon DH.** Book review of "Poison Pills: The Untold Story of the Vioxx Drug Scandal". *J Clin Invest* 2009;119:427.
47. Ridker PM, **Solomon DH.** Should patients with rheumatoid arthritis receive statin therapy? Implications of the JUPITER trial for the arthritis community. *Arthritis Rheum* 2009;60:1205-9.
48. **Solomon DH,** Rekedal L, Cadarette SM. Osteoporosis treatments and adverse events. *Curr Opin Rheumatol* 2009;21:363-8.
49. Parikh S, Avorn J, **Solomon DH.** Pharmacological management of osteoporosis in nursing home populations: a systematic review. *J Am Geriatrics Society* 2009;57:327-34.
50. **Solomon, DH.** Searching for a safe analgesic in patients with cardiovascular disease. *Circulation: Cardiovascular Outcomes and Quality* 2009;2:146-7.
51. **Solomon DH,** Gabriel SE. Moving forward with quality: pay for reporting meets rheumatology. *Arthritis Rheum (Arthritis Care & Research)* 2009;57:703-4.
52. Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, **Solomon DH.** Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. *Osteoporosis Int* 2009;20:2127-34.
53. **Solomon DH,** Gabriel SE. A call for evidence-based quality measures: a goal worthy of pursuit. *Nat Clin Practice Rheumatol* 2009;3:363.
54. **Solomon DH,** Kim SY. Tumor necrosis factor blockade and the risk of viral infection. *Nat Rev Rheumatol* 2010;6(3):165-74.
55. Kesselheim AS, **Solomon DH.** Incentives for drug development – the curious case of Colchicine. *N Engl J Med* 2010; 362:2045-8.
56. **Solomon DH.** Strategies for making analgesia safer: The role for comparative effectiveness research. *Arthritis Rheum* 2010;62:1568-70.
57. Desai SP, **Solomon DH.** The use of glucocorticoids in rheumatoid arthritis - no "rational" approach yet. *Arthritis Res Ther* 2010; 25:127. **PMCID: PMC2911892**
58. SY Kim and **DH Solomon:** Comparative safety of NSAIDs: *Nat Rev Cardiol* 2011 8(4): 193–195.
59. **Solomon DH.** Postfracture interventions disseminated through health care and drug insurers. *Osteoporosis Int* 2011;Suppl 3:S465-S469.
60. Adler RA, Bates DW, Dell RM, Leboff MS, Majumdar SR, Saag KG, **Solomon DH,** Suarez-Almazor ME. Systems-based approaches to osteoporosis and fracture care: policy and research recommendations from the workgroups. *Osteoporosis Int* 2011;Suppl 3:S495-S500.
61. Kim S, **Solomon D.** Use of administrative claims data for comparative effectiveness research of rheumatoid arthritis treatments. *Arthritis Res Ther.* 2011 **13:129** (7 October 2011) .

62. Desai SP, **Solomon DH**. A new paradigm of quality of care in rheumatoid arthritis: how our new therapeutics have changed the game. *Arthritis Research & Therapy* 2013, 15:121
63. Yoshida K, Radner H, Kavanaugh A, Sung Y, Bae S, Kishimoto M, Matsui K, Okada M, Tohma S, Weinblatt M, **Solomon DH**. Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. *Clin Exp Rheumatol* 2013; 31 (Suppl. 78): S28-S32.
64. Massarotti EM, **Solomon DH**. The potential role of 'non-rheumatic' therapies in rheumatic disease. *Arthritis Research & Therapy*.2013, 15:124.
65. **Solomon DH**, Bitton A, Katz JN, Radner H, Brown E, Fraenkel L. Treat to Target in Rheumatoid Arthritis: Fact, Fiction or Hypothesis? *Arthritis Rheumatism* 2014;66(4):775-82.
66. Yoshida K, **Solomon DH**, Kim SC. Active comparator design and new user design in observational studies. *Nat Rev Rheumatol* 2015;11(7):437-41.
67. Daugherty SE, Lee SB, Nowell B, Peay H, **Solomon DH**, Valbrun TG, Velentgas P, Whicher D. The Increasing Focus on the Patient in Patient Registries. In: *Patient-Centricity and Registries – Ethics and Engagement*. E-book Supplement to *Registries for Evaluating Patient Outcomes: A User's Guide*. AHRQ Publication No. TBD. Rockville, MD: Agency for Healthcare Research and Quality. 2016.
68. **Solomon DH**, Bucala RJ. The enduring value of reporting randomized controlled clinical trials in *Arthritis & Rheumatology*: 2016 and beyond. *Arthritis Rheumatol* 2016;68:2831-2833.
69. Radner H, **Solomon DH**. Multimorbidity, Chapter 43 in *Rheumatology*, Editors Hochberg, Gravallese, Silman, Smolen, Weinblatt, and Weisman. Elsevier. 2017.
70. **Solomon DH**. UpToDate. Chapters on NSAIDs and Coxib safety. 2010-present. Waltham, MA.
71. Bathon JM, Giles JT, **Solomon DH**. TNF antagonists: Killing two birds with one biologic stone. *Arthritis Rheumatol* 2017, in press.
72. Smolen J, Yamamoto K, Barton A, McInnes I, Firestein G, Strand V, Aletaha D, **Solomon DH**, Emery P, Burmester G, Kavanaugh A. Rheumatoid Arthritis. *Nature Reviews Disease Primers*. 2018.

Non-peer reviewed scientific or medical publications/materials in print or other media

Letters to the Editor

1. **Solomon DH**, Avorn J. Gastrointestinal complications of non-steroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. *Am J Med* 1995;99:441-2.
2. **Solomon DH**. Reducing serologic tests for rheumatic diseases. *J Rheumatol* 2000;27:1565.

3. Amaravadi RK, Jacobson BC, **Solomon DH**, Fischer MA. Acute pancreatitis associated with rofecoxib. *Am J Gastroenterol* 2002;97:1077-8.
4. **Solomon DH**, Glynn RJ, Avorn J. NSAIDs and myocardial infarction. *Lancet* 2002;360:90.
5. **Solomon DH**, LaValley MP, Wang PS, Avorn J. What are the real effects of the arthritis self-management programs on pain and disability. *Arthritis Rheum* 2004;50:1012-13.
6. Schneeweiss S, **Solomon DH**. Not so surprising (Letter regarding Comparison on evidence of harms of medical interventions in randomized and non-randomized). *CMAJ* 2006, electronic before print. **PMCID: PMC1489992**
7. **Solomon DH**, Avorn J, Wang PS, Vaillant G, Cabral D, Mogun H, Sturmer T. Opioid usage among older adults with low back pain. *Arthritis Rheum (Arthritis Care & Research)* 2006;65:513-514.
8. Cadarette SM, Katz JN, **Solomon DH**. Did prescription bias affect outcomes in a study of the relative effectiveness of osteoporosis drugs? In response [letter]. *Ann Intern Med* 2008;149:514.
9. **Solomon DH**, Patrick AR, Brookhart MA. Esophageal cancer and bisphosphonates [letter]. *New Engl J Med* 2009;360:1789-190.

Narrative Report

Dr. Solomon is primarily a population scientist focusing on the epidemiology and health services of rheumatic disease. He serves as the Chief of the Section of Clinical Sciences in the Division of Rheumatology at BWH. His research work is primarily funded by the NIH, AHRQ, and foundations. He has served major roles at the American College of Rheumatology and within the osteoporosis community as well. Currently, Dr. Solomon spends 85% of his time on research and mentoring junior investigators, 5% on administrative responsibilities, and 10% on clinical care. His teaching is primarily through his research mentoring as well as Co-Directing the musculoskeletal pathophysiology course for Harvard Medical School-Massachusetts Institute of Technology HST program. He also precepts in Rheumatology clinic and attends on the Rheumatology consult service.

His **achievements in population science research** focuses on three areas. First, Dr. Solomon has been a leading investigator on the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs). He served on the Executive Committee of the PRECISION trial and has been the first author on 12 original articles in this area, has had several industry-sponsored grants and one AHRQ sponsored grant in this area. As well, he led the American College of Rheumatology Blue Ribbon Panel to set recommendations for NSAIDs. He has given over 15 invited talks on this topic and currently serves on the Executive Committee of the largest randomized controlled trial on the cardiovascular safety of NSAIDs and selective COX-2 inhibitors, on the DSMB of two RCTs in rheumatology, and as a consultant to the FDA on the Safety of Arthritis drugs.

Second, Dr. Solomon has focused much of his research on **cardiovascular manifestations of rheumatoid arthritis and its treatment**. He completed one NIH grant on this topic and is the co-Principal Investigator on an NIH funded U01 studying cardiovascular disease in rheumatoid arthritis. This is a 35 site trial testing different treatment strategies and their effect on cardiovascular risk. He also recently developed a rheumatoid arthritis specific cardiovascular risk score. He is the first author on 6 publications describing the epidemiology of cardiovascular disease in patients with rheumatoid arthritis. He has given 15 invited lectures in this area.

Finally, Dr Solomon has helped **define standards for osteoporosis care improvement**. He has received two NIH grants in this area. He recently completed an NIH funded large-scale adherence improvement trial for osteoporosis medications. He has first authored 8 original articles in this area. He has given 10 invited lectures on osteoporosis improvement. He currently serves on the Governing Committee of the National Bone Health Association, focusing on methods to improve dissemination of proven improvement methods.

Dr. Solomon teaches and mentors primarily in rheumatic disease epidemiology and pharmacoepidemiology. He has mentored 37 fellows and trainees and has a K24 award from NIH with 25% effort devoted to research training and mentoring. He developed and directed a course in clinical research for rheumatologists and is currently working on a similar course with longitudinal mentoring. He teaches residents in the BWH Department of Medicine's lecture series and journal club.

In summary, Dr. Solomon is an expert in rheumatic disease epidemiology with a focus on drug safety and cardiovascular outcomes. He has demonstrated expertise in these areas with grants, papers, and lectures. As well, he has received funding to mentor rheumatologists in drug safety epidemiology. He plays leadership roles at BWH and in relevant professional societies.